Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,23293039,total chromatographic run time,"The total chromatographic run time was 8.0 min, with retention times of 3.0 and 2.9 min for MET and IS-1, respectively, and 6.1 and 4.9 min for PIO and IS-2.",Simultaneous determination and pharmacokinetic study of metformin and pioglitazone in dog plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293039/),min,8.0,2451,DB01132,Pioglitazone
,23293039,retention times,"The total chromatographic run time was 8.0 min, with retention times of 3.0 and 2.9 min for MET and IS-1, respectively, and 6.1 and 4.9 min for PIO and IS-2.",Simultaneous determination and pharmacokinetic study of metformin and pioglitazone in dog plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293039/),min,3.0,2452,DB01132,Pioglitazone
,23293039,retention times,"The total chromatographic run time was 8.0 min, with retention times of 3.0 and 2.9 min for MET and IS-1, respectively, and 6.1 and 4.9 min for PIO and IS-2.",Simultaneous determination and pharmacokinetic study of metformin and pioglitazone in dog plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293039/),min,2.9,2453,DB01132,Pioglitazone
,23293039,retention times,"The total chromatographic run time was 8.0 min, with retention times of 3.0 and 2.9 min for MET and IS-1, respectively, and 6.1 and 4.9 min for PIO and IS-2.",Simultaneous determination and pharmacokinetic study of metformin and pioglitazone in dog plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293039/),min,6.1,2454,DB01132,Pioglitazone
,23293039,retention times,"The total chromatographic run time was 8.0 min, with retention times of 3.0 and 2.9 min for MET and IS-1, respectively, and 6.1 and 4.9 min for PIO and IS-2.",Simultaneous determination and pharmacokinetic study of metformin and pioglitazone in dog plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293039/),min,4.9,2455,DB01132,Pioglitazone
,23293039,recoveries,The recoveries ranged from 96.4 to 112.8% for MET and 102.1 to 104.5% for PIO.,Simultaneous determination and pharmacokinetic study of metformin and pioglitazone in dog plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293039/),%,96.4 to 112.8,2456,DB01132,Pioglitazone
,23293039,recoveries,The recoveries ranged from 96.4 to 112.8% for MET and 102.1 to 104.5% for PIO.,Simultaneous determination and pharmacokinetic study of metformin and pioglitazone in dog plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293039/),%,102.1 to 104.5,2457,DB01132,Pioglitazone
,21058416,flow rate,The mobile phase used was acetonitrile and 50 mm ammonium acetate buffer at a flow rate of 1 mL/min.,Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),[ml] / [min],1,3720,DB01132,Pioglitazone
,21058416,retention times,"The retention times for pioglitazone, felodipine and nitrendipine were found to be 5.12, 10.53 and 7.14 min, respectively.",Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),min,5.12,3721,DB01132,Pioglitazone
,21058416,retention times,"The retention times for pioglitazone, felodipine and nitrendipine were found to be 5.12, 10.53 and 7.14 min, respectively.",Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),min,10.53,3722,DB01132,Pioglitazone
,21058416,retention times,"The retention times for pioglitazone, felodipine and nitrendipine were found to be 5.12, 10.53 and 7.14 min, respectively.",Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),min,7.14,3723,DB01132,Pioglitazone
,21058416,C(Max),"The C(Max) , T(Max) , and AUC(0-24) of pioglitazone and felodipine from buccal tablet were found to be 394.6 ng/mL, 5.6 h, 2624.2 ng h/mL and 44.4 ng/mL, 5.5 h, 275.8 ng h/mL, respectively.",Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),[ng] / [ml],394.6,3724,DB01132,Pioglitazone
,21058416,T(Max),"The C(Max) , T(Max) , and AUC(0-24) of pioglitazone and felodipine from buccal tablet were found to be 394.6 ng/mL, 5.6 h, 2624.2 ng h/mL and 44.4 ng/mL, 5.5 h, 275.8 ng h/mL, respectively.",Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),h,5.6,3725,DB01132,Pioglitazone
,21058416,T(Max),"The C(Max) , T(Max) , and AUC(0-24) of pioglitazone and felodipine from buccal tablet were found to be 394.6 ng/mL, 5.6 h, 2624.2 ng h/mL and 44.4 ng/mL, 5.5 h, 275.8 ng h/mL, respectively.",Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),[h·ng] / [ml],2624.2,3726,DB01132,Pioglitazone
,21058416,T(Max),"The C(Max) , T(Max) , and AUC(0-24) of pioglitazone and felodipine from buccal tablet were found to be 394.6 ng/mL, 5.6 h, 2624.2 ng h/mL and 44.4 ng/mL, 5.5 h, 275.8 ng h/mL, respectively.",Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),[ng] / [ml],44.4,3727,DB01132,Pioglitazone
,21058416,T(Max),"The C(Max) , T(Max) , and AUC(0-24) of pioglitazone and felodipine from buccal tablet were found to be 394.6 ng/mL, 5.6 h, 2624.2 ng h/mL and 44.4 ng/mL, 5.5 h, 275.8 ng h/mL, respectively.",Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),h,5.5,3728,DB01132,Pioglitazone
,21058416,AUC(0-24),"The C(Max) , T(Max) , and AUC(0-24) of pioglitazone and felodipine from buccal tablet were found to be 394.6 ng/mL, 5.6 h, 2624.2 ng h/mL and 44.4 ng/mL, 5.5 h, 275.8 ng h/mL, respectively.",Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),[h·ng] / [ml],275.8,3729,DB01132,Pioglitazone
,15900286,elimination half-life (t (1/2) ),"Gemfibrozil alone raised the mean total area under the plasma concentration-time curve from time 0 to infinity [AUC(0-infinity)] of pioglitazone 3.2-fold (range, 2.3-fold to 6.5-fold; P < .001) and prolonged its elimination half-life (t (1/2) ) from 8.3 to 22.7 hours ( P < .001) but had no significant effect on its peak concentration (C max ) compared with placebo (control).","Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900286/),h,8.3 to 22.7,4948,DB01132,Pioglitazone
,24561309,flow rate,"After extraction of the plasma samples with ethyl acetate, the separation of pioglitazone enantiomers and internal standard (I.S., dexamethasone acetate) was achieved on a cellulose tris (3,5-dichlorophenylcarbamate) column known as Chiralpak IC with a mobile phase of hexane-isopropanol (70:30, v/v) at a flow rate of 1.0mL/min.",Chiral liquid chromatography resolution and stereoselective pharmacokinetic study of pioglitazone enantiomers in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24561309/),[ml] / [min],1.0,7119,DB01132,Pioglitazone
,24561309,extraction recoveries,The mean extraction recoveries were 82.37-91.38% for pioglitazone enantiomers and 95.76% for I.S. from rat plasma.,Chiral liquid chromatography resolution and stereoselective pharmacokinetic study of pioglitazone enantiomers in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24561309/),%,82.37-91.38,7120,DB01132,Pioglitazone
,24561309,extraction recoveries,The mean extraction recoveries were 82.37-91.38% for pioglitazone enantiomers and 95.76% for I.S. from rat plasma.,Chiral liquid chromatography resolution and stereoselective pharmacokinetic study of pioglitazone enantiomers in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24561309/),%,95.76,7121,DB01132,Pioglitazone
,25283698,lag time,"The tablets of the optimized formulation floated on the test medium for more than 24 h with 5 min of floating lag time, and sustained MH release for 12 h via a diffusion-dependent manner; and complete release of PG within 5 min were achieved.",Gastro-floating bilayer tablets for the sustained release of metformin and immediate release of pioglitazone: preparation and in vitro/in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25283698/),min,5,8357,DB01132,Pioglitazone
,31836899,limit of detection,"In this study, an alternative, a simple, sensitive high-performance liquid chromatography method has been developed (limit of detection: 15 ng/mL and limit of quantification: 50 ng/mL) for simultaneous estimation of this drug combination in rat plasma.",Simultaneous Pharmacokinetics Estimation of Nateglinide and Pioglitazone by RP-HPLC: Computational Study to Unlock the Synergism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31836899/),[ng] / [ml],15,13370,DB01132,Pioglitazone
,31836899,limit of quantification,"In this study, an alternative, a simple, sensitive high-performance liquid chromatography method has been developed (limit of detection: 15 ng/mL and limit of quantification: 50 ng/mL) for simultaneous estimation of this drug combination in rat plasma.",Simultaneous Pharmacokinetics Estimation of Nateglinide and Pioglitazone by RP-HPLC: Computational Study to Unlock the Synergism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31836899/),[ng] / [ml],50,13371,DB01132,Pioglitazone
,31836899,flow rate,"Using a Waters Nova-Pak C 18 column (150 × 3.9 mm, 4 μm) and a mobile phase of acetonitrile: 10 mM KH2PO4 (60: 40, V/V (volume by volume)) pH 3.5, the analysis was performed at 210 nm with a flow rate of 1.5 mL/min.",Simultaneous Pharmacokinetics Estimation of Nateglinide and Pioglitazone by RP-HPLC: Computational Study to Unlock the Synergism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31836899/),[ml] / [min],1.5,13372,DB01132,Pioglitazone
,24937378,flux,The prepared NLCs had a mean size of 166.05 nm and drug loading of 10.41% with flux value of 47.36 µg/cm(2)/h.,Nanostructured lipid carriers of pioglitazone for transdermal application: from experimental design to bioactivity detail. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24937378/),[μg] / [cm(2)·h],47.36,16135,DB01132,Pioglitazone
>,24937378,entrapment,The entrapment of PZ is >70% in the NLCs with enhancement ratio of 3.2 times.,Nanostructured lipid carriers of pioglitazone for transdermal application: from experimental design to bioactivity detail. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24937378/),%,70,16136,DB01132,Pioglitazone
,24937378,shelf life,The shelf life of the optimized formulation was found to be 1.83 years.,Nanostructured lipid carriers of pioglitazone for transdermal application: from experimental design to bioactivity detail. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24937378/),years,1.83,16137,DB01132,Pioglitazone
,30058540,flow rate,"The mobile phase comprises of Acetonitrile, 0.1 M ammonium acetate and glacial acetic acid (25:25:1 v/v/v) at a flow rate of 1.2 mL/min., using Macherey-Nagel Column C18, (dimensions: 5 μm; 250 × 4.6mm) with a guard column.",Development and validation of HPLC method for the determination of pioglitazone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30058540/),[ml] / [min],1.2,21902,DB01132,Pioglitazone
,30058540,limit of detection,"The present method showed good linearity (R2=0.9998) from 0.1 to 2.0µg/ml standards, with a limit of detection 0.1 µg/ml.",Development and validation of HPLC method for the determination of pioglitazone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30058540/),[μg] / [ml],0.1,21903,DB01132,Pioglitazone
,22484334,EC (50),"In transient transactivation assay in NIH3T3 cells, NS-1 showed a partial activation against human PPARγ with an EC (50) of 0.91 μM without activating human PPARα and PPARδ.",NS-1: a novel partial peroxisome proliferator-activated receptor γ agonist to improve insulin sensitivity and metabolic profile. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22484334/),μM,0.91,22957,DB01132,Pioglitazone
,22484334,Cmax,"NS-1 showed good in vivo pharmacokinetic profiles in C57BL/6J mice at 30 mg/kg oral dose with Cmax-26 μM, terminal elimination half-life- 2.5h and bioavailability of 85%.",NS-1: a novel partial peroxisome proliferator-activated receptor γ agonist to improve insulin sensitivity and metabolic profile. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22484334/),μM,26,22958,DB01132,Pioglitazone
,22484334,terminal elimination half-life,"NS-1 showed good in vivo pharmacokinetic profiles in C57BL/6J mice at 30 mg/kg oral dose with Cmax-26 μM, terminal elimination half-life- 2.5h and bioavailability of 85%.",NS-1: a novel partial peroxisome proliferator-activated receptor γ agonist to improve insulin sensitivity and metabolic profile. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22484334/),h,2.5,22959,DB01132,Pioglitazone
,22484334,bioavailability,"NS-1 showed good in vivo pharmacokinetic profiles in C57BL/6J mice at 30 mg/kg oral dose with Cmax-26 μM, terminal elimination half-life- 2.5h and bioavailability of 85%.",NS-1: a novel partial peroxisome proliferator-activated receptor γ agonist to improve insulin sensitivity and metabolic profile. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22484334/),%,85,22960,DB01132,Pioglitazone
,25854855,recoveries,The mean recoveries of rosiglitazone from DBS and urine were 93.30% and 92.49% respectively.,LC-MS/MS method for the determination of rosiglitazone on rat dried blood spots and rat urine: Application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25854855/),%,93.30,27915,DB01132,Pioglitazone
,25854855,recoveries,The mean recoveries of rosiglitazone from DBS and urine were 93.30% and 92.49% respectively.,LC-MS/MS method for the determination of rosiglitazone on rat dried blood spots and rat urine: Application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25854855/),%,92.49,27916,DB01132,Pioglitazone
,25854855,limit of detections,The limit of detections and quantifications were 0.015 and 0.052 ng/mL in DBS and 0.023 and 0.075 ng/mL in urine samples respectively.,LC-MS/MS method for the determination of rosiglitazone on rat dried blood spots and rat urine: Application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25854855/),[ng] / [ml],0.015,27917,DB01132,Pioglitazone
,25854855,limit of detections,The limit of detections and quantifications were 0.015 and 0.052 ng/mL in DBS and 0.023 and 0.075 ng/mL in urine samples respectively.,LC-MS/MS method for the determination of rosiglitazone on rat dried blood spots and rat urine: Application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25854855/),[ng] / [ml],0.052,27918,DB01132,Pioglitazone
,25854855,limit of detections,The limit of detections and quantifications were 0.015 and 0.052 ng/mL in DBS and 0.023 and 0.075 ng/mL in urine samples respectively.,LC-MS/MS method for the determination of rosiglitazone on rat dried blood spots and rat urine: Application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25854855/),[ng] / [ml],0.023,27919,DB01132,Pioglitazone
,25854855,limit of detections,The limit of detections and quantifications were 0.015 and 0.052 ng/mL in DBS and 0.023 and 0.075 ng/mL in urine samples respectively.,LC-MS/MS method for the determination of rosiglitazone on rat dried blood spots and rat urine: Application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25854855/),[ng] / [ml],0.075,27920,DB01132,Pioglitazone
,7956739,peak plasma concentration,The peak plasma concentration of 10 micrograms/ml occurred 1 hr after dosing at 10 mg/kg p.o.; the apparent plasma terminal half-life was 7.5 hr.,Disposition and metabolism of the hypoglycemic agent pioglitazone in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7956739/),[μg] / [ml],10,28599,DB01132,Pioglitazone
,7956739,apparent plasma terminal half-life,The peak plasma concentration of 10 micrograms/ml occurred 1 hr after dosing at 10 mg/kg p.o.; the apparent plasma terminal half-life was 7.5 hr.,Disposition and metabolism of the hypoglycemic agent pioglitazone in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7956739/),h,7.5,28600,DB01132,Pioglitazone
,27659416,flow rate,The mobile phase was run at a flow rate of 1mL/min and the sample injection was 10μL.,Liquid chromatography and tandem mass spectrometry method for quantitative determination of pioglitazone and its metabolite 5-hydroxy pioglitazone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27659416/),[ml] / [min],1,32300,DB01132,Pioglitazone
,27659416,extraction recovery,The mean extraction recovery of PIO & HPIO from the spiked plasma was found to be 94.92% for pioglitazone and 96.13% for 5-hydroxy pioglitazone.,Liquid chromatography and tandem mass spectrometry method for quantitative determination of pioglitazone and its metabolite 5-hydroxy pioglitazone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27659416/),%,94.92,32301,DB01132,Pioglitazone
,27659416,extraction recovery,The mean extraction recovery of PIO & HPIO from the spiked plasma was found to be 94.92% for pioglitazone and 96.13% for 5-hydroxy pioglitazone.,Liquid chromatography and tandem mass spectrometry method for quantitative determination of pioglitazone and its metabolite 5-hydroxy pioglitazone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27659416/),%,96.13,32302,DB01132,Pioglitazone
,24798870,tmax,"Absorption of JNJ-41443532 into the systemic circulation occurred at a median tmax of 2 h, and the mean t½ was approximately 8 h for both doses; plasma systemic exposures increased slightly more than dose-proportionally.","CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24798870/),h,2,33239,DB01132,Pioglitazone
,24798870,t½,"Absorption of JNJ-41443532 into the systemic circulation occurred at a median tmax of 2 h, and the mean t½ was approximately 8 h for both doses; plasma systemic exposures increased slightly more than dose-proportionally.","CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24798870/),h,8,33240,DB01132,Pioglitazone
,17214065,time to maximum concentration (Tmax),"After a single oral dose of 30 mg pioglitazone tablet, the drug was absorbed into systemic circulation with time to maximum concentration (Tmax) at 2.00 +/- 1.61 (0.5-6) hr, and the plasma level reached the maximum concentration (Cmax) of 1.14 +/- 0.29 (0.47-1.63) microg/ml.",The pharmacokinetics of pioglitazone in Thai healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17214065/),h,2.00,35024,DB01132,Pioglitazone
,17214065,maximum concentration (Cmax),"After a single oral dose of 30 mg pioglitazone tablet, the drug was absorbed into systemic circulation with time to maximum concentration (Tmax) at 2.00 +/- 1.61 (0.5-6) hr, and the plasma level reached the maximum concentration (Cmax) of 1.14 +/- 0.29 (0.47-1.63) microg/ml.",The pharmacokinetics of pioglitazone in Thai healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17214065/),[μg] / [ml],1.14,35025,DB01132,Pioglitazone
,17214065,AUC,The AUC was 11.47 +/- 4.77 and 16.69 +/- 7.75 microg x hr/ml for AUC(0-t) and AUC(0-inf) respectively.,The pharmacokinetics of pioglitazone in Thai healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17214065/),[h·μg] / [ml],11.47,35026,DB01132,Pioglitazone
,17214065,AUC,The AUC was 11.47 +/- 4.77 and 16.69 +/- 7.75 microg x hr/ml for AUC(0-t) and AUC(0-inf) respectively.,The pharmacokinetics of pioglitazone in Thai healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17214065/),[h·μg] / [ml],16.69,35027,DB01132,Pioglitazone
,17214065,AUC(0-t),The AUC was 11.47 +/- 4.77 and 16.69 +/- 7.75 microg x hr/ml for AUC(0-t) and AUC(0-inf) respectively.,The pharmacokinetics of pioglitazone in Thai healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17214065/),[h·μg] / [ml],16.69,35028,DB01132,Pioglitazone
,17214065,elimination rate constant (Kel),"The elimination rate constant (Kel) of pioglitazone obtained was 0.08 +/- 0.04 hr(-1), whereas the t1/2 was 11.19 +/- 7.38 hrs with the clearance (Cl) of 2.26 +/- 1.22 L/hr.",The pharmacokinetics of pioglitazone in Thai healthy subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17214065/),1/[hr],0.08,35029,DB01132,Pioglitazone
,17214065,t1/2,"The elimination rate constant (Kel) of pioglitazone obtained was 0.08 +/- 0.04 hr(-1), whereas the t1/2 was 11.19 +/- 7.38 hrs with the clearance (Cl) of 2.26 +/- 1.22 L/hr.",The pharmacokinetics of pioglitazone in Thai healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17214065/),h,11.19,35030,DB01132,Pioglitazone
,17214065,clearance (Cl),"The elimination rate constant (Kel) of pioglitazone obtained was 0.08 +/- 0.04 hr(-1), whereas the t1/2 was 11.19 +/- 7.38 hrs with the clearance (Cl) of 2.26 +/- 1.22 L/hr.",The pharmacokinetics of pioglitazone in Thai healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17214065/),[l] / [h],2.26,35031,DB01132,Pioglitazone
,17214065,apparent volume of distribution (Vd),The apparent volume of distribution (Vd) was found to be 30.19 +/- 13.06 L.,The pharmacokinetics of pioglitazone in Thai healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17214065/),l,30.19,35032,DB01132,Pioglitazone
,22587345,AUC(inf),"Similarly, multiple doses of sitagliptin, pioglitazone or glimepiride did not change the pharmacokinetics of a single dose of ipragliflozin (AUC(inf) : 95.0 [93.4-103.1], 100.0 [98.1-102.0], 99.1 [96.6-101.6]; and C(max) : 96.5 [90.4-103.1], 93.5 [86.3-101.2], 97.3 [89.2-106.2]).","No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22587345/),,95.0,39663,DB01132,Pioglitazone
,22587345,AUC(inf),"Similarly, multiple doses of sitagliptin, pioglitazone or glimepiride did not change the pharmacokinetics of a single dose of ipragliflozin (AUC(inf) : 95.0 [93.4-103.1], 100.0 [98.1-102.0], 99.1 [96.6-101.6]; and C(max) : 96.5 [90.4-103.1], 93.5 [86.3-101.2], 97.3 [89.2-106.2]).","No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22587345/),,100.0,39664,DB01132,Pioglitazone
,22587345,AUC(inf),"Similarly, multiple doses of sitagliptin, pioglitazone or glimepiride did not change the pharmacokinetics of a single dose of ipragliflozin (AUC(inf) : 95.0 [93.4-103.1], 100.0 [98.1-102.0], 99.1 [96.6-101.6]; and C(max) : 96.5 [90.4-103.1], 93.5 [86.3-101.2], 97.3 [89.2-106.2]).","No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22587345/),,99.1,39665,DB01132,Pioglitazone
,22587345,C(max),"Similarly, multiple doses of sitagliptin, pioglitazone or glimepiride did not change the pharmacokinetics of a single dose of ipragliflozin (AUC(inf) : 95.0 [93.4-103.1], 100.0 [98.1-102.0], 99.1 [96.6-101.6]; and C(max) : 96.5 [90.4-103.1], 93.5 [86.3-101.2], 97.3 [89.2-106.2]).","No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22587345/),,96.5,39666,DB01132,Pioglitazone
,22587345,C(max),"Similarly, multiple doses of sitagliptin, pioglitazone or glimepiride did not change the pharmacokinetics of a single dose of ipragliflozin (AUC(inf) : 95.0 [93.4-103.1], 100.0 [98.1-102.0], 99.1 [96.6-101.6]; and C(max) : 96.5 [90.4-103.1], 93.5 [86.3-101.2], 97.3 [89.2-106.2]).","No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22587345/),,93.5,39667,DB01132,Pioglitazone
,22587345,C(max),"Similarly, multiple doses of sitagliptin, pioglitazone or glimepiride did not change the pharmacokinetics of a single dose of ipragliflozin (AUC(inf) : 95.0 [93.4-103.1], 100.0 [98.1-102.0], 99.1 [96.6-101.6]; and C(max) : 96.5 [90.4-103.1], 93.5 [86.3-101.2], 97.3 [89.2-106.2]).","No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22587345/),,97.3,39668,DB01132,Pioglitazone
,11831892,EC(50),"Synthesis and structure-activity relationships of tricyclic alpha-ethoxy-phenylpropionic acid derivatives guided by in vitro PPARalpha and PPARgamma transactivation data and computer modeling led to the identification of the novel carbazole analogue, 3q, with dual PPARalpha (EC(50) = 0.36 microM) and PPARgamma (EC(50) = 0.17 microM) activity in vitro.",Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11831892/),μM,0.36,41150,DB01132,Pioglitazone
,11831892,EC(50),"Synthesis and structure-activity relationships of tricyclic alpha-ethoxy-phenylpropionic acid derivatives guided by in vitro PPARalpha and PPARgamma transactivation data and computer modeling led to the identification of the novel carbazole analogue, 3q, with dual PPARalpha (EC(50) = 0.36 microM) and PPARgamma (EC(50) = 0.17 microM) activity in vitro.",Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11831892/),μM,0.17,41151,DB01132,Pioglitazone
,23732843,m/,"The ion transitions were monitored at m/z 357.2→134.2 for PIO, 373.0→150.1 for OH-PIO, 130.2→71.0 for MET, 361.1→134.2 for PIO-IS and 136.1→77.1 for MET-IS.","Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23732843/),,357.2,51277,DB01132,Pioglitazone
,23732843,m/,"The ion transitions were monitored at m/z 357.2→134.2 for PIO, 373.0→150.1 for OH-PIO, 130.2→71.0 for MET, 361.1→134.2 for PIO-IS and 136.1→77.1 for MET-IS.","Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23732843/),,134.2,51278,DB01132,Pioglitazone
,23732843,m/,"The ion transitions were monitored at m/z 357.2→134.2 for PIO, 373.0→150.1 for OH-PIO, 130.2→71.0 for MET, 361.1→134.2 for PIO-IS and 136.1→77.1 for MET-IS.","Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23732843/),,373.0,51279,DB01132,Pioglitazone
,23732843,m/,"The ion transitions were monitored at m/z 357.2→134.2 for PIO, 373.0→150.1 for OH-PIO, 130.2→71.0 for MET, 361.1→134.2 for PIO-IS and 136.1→77.1 for MET-IS.","Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23732843/),,150.1,51280,DB01132,Pioglitazone
,23732843,m/,"The ion transitions were monitored at m/z 357.2→134.2 for PIO, 373.0→150.1 for OH-PIO, 130.2→71.0 for MET, 361.1→134.2 for PIO-IS and 136.1→77.1 for MET-IS.","Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23732843/),,130.2,51281,DB01132,Pioglitazone
,23732843,m/,"The ion transitions were monitored at m/z 357.2→134.2 for PIO, 373.0→150.1 for OH-PIO, 130.2→71.0 for MET, 361.1→134.2 for PIO-IS and 136.1→77.1 for MET-IS.","Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23732843/),,71.0,51282,DB01132,Pioglitazone
,23732843,m/,"The ion transitions were monitored at m/z 357.2→134.2 for PIO, 373.0→150.1 for OH-PIO, 130.2→71.0 for MET, 361.1→134.2 for PIO-IS and 136.1→77.1 for MET-IS.","Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23732843/),,361.1,51283,DB01132,Pioglitazone
,23732843,m/,"The ion transitions were monitored at m/z 357.2→134.2 for PIO, 373.0→150.1 for OH-PIO, 130.2→71.0 for MET, 361.1→134.2 for PIO-IS and 136.1→77.1 for MET-IS.","Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23732843/),,134.2,51284,DB01132,Pioglitazone
,23732843,m/,"The ion transitions were monitored at m/z 357.2→134.2 for PIO, 373.0→150.1 for OH-PIO, 130.2→71.0 for MET, 361.1→134.2 for PIO-IS and 136.1→77.1 for MET-IS.","Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23732843/),,136.1,51285,DB01132,Pioglitazone
,23732843,total chromatographic run time,The total chromatographic run time was 4.0min.,"Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23732843/),min,4.0,51286,DB01132,Pioglitazone
>,25924888,bioavailability,SC bioavailability of hIgG in all animal groups was similar (>84%).,Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25924888/),%,84,52620,DB01132,Pioglitazone
,30633968,IC50,Saroglitazar showed CYP2C8 inhibition in human liver microsomes (IC50: 2.9 μM).,"Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30633968/),μM,2.9,57230,DB01132,Pioglitazone
,30633968,IC50,"The CYP2C8 IC50 of 4.5 μM in RLM for saroglitazar, supported the use of rats for this DDI study.","Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30633968/),μM,4.5,57231,DB01132,Pioglitazone
,22612529,bioavailability,"After oral administration, mean bioavailability was 55%, t(1/2) was 3.5 h, T(max) was 3.6 h, C(max) was 2131 ng/mL, and AUC(0-∞) was 15 556 ng/mL · h.",Pharmacokinetics of pioglitazone in lean and obese cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22612529/),%,55,64209,DB01132,Pioglitazone
,22612529,t(1/2),"After oral administration, mean bioavailability was 55%, t(1/2) was 3.5 h, T(max) was 3.6 h, C(max) was 2131 ng/mL, and AUC(0-∞) was 15 556 ng/mL · h.",Pharmacokinetics of pioglitazone in lean and obese cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22612529/),h,3.5,64210,DB01132,Pioglitazone
,22612529,T(max),"After oral administration, mean bioavailability was 55%, t(1/2) was 3.5 h, T(max) was 3.6 h, C(max) was 2131 ng/mL, and AUC(0-∞) was 15 556 ng/mL · h.",Pharmacokinetics of pioglitazone in lean and obese cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22612529/),h,3.6,64211,DB01132,Pioglitazone
,22612529,C(max),"After oral administration, mean bioavailability was 55%, t(1/2) was 3.5 h, T(max) was 3.6 h, C(max) was 2131 ng/mL, and AUC(0-∞) was 15 556 ng/mL · h.",Pharmacokinetics of pioglitazone in lean and obese cats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22612529/),[ng] / [ml],2131,64212,DB01132,Pioglitazone
,22612529,AUC(0-∞),"After oral administration, mean bioavailability was 55%, t(1/2) was 3.5 h, T(max) was 3.6 h, C(max) was 2131 ng/mL, and AUC(0-∞) was 15 556 ng/mL · h.",Pharmacokinetics of pioglitazone in lean and obese cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22612529/),[ng] / [h·ml],15 556,64213,DB01132,Pioglitazone
,16172178,half-life,"The mean half-life was 8 to 9 hours for pioglitazone and 24 to 32 hours for M-III and M-IV, with similar values at each dose level.",Single- and multiple-dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172178/),h,8 to 9,64339,DB01132,Pioglitazone
,16172178,half-life,"The mean half-life was 8 to 9 hours for pioglitazone and 24 to 32 hours for M-III and M-IV, with similar values at each dose level.",Single- and multiple-dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172178/),h,24 to 32,64340,DB01132,Pioglitazone
,23057002,T(max),The best formulation has shown T(max) of 1 hour which was highly significant (P < 0.01) when compared with pure drug and marketed formulation.,In vitro-in vivo evaluation of fast-dissolving tablets containing solid dispersion of pioglitazone hydrochloride. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23057002/),h,1,69984,DB01132,Pioglitazone
,16815107,flow rate,"Chromatographic separation was achieved with a reversed-phase Apollo C18 column and a mobile phase of methanol-acetonitrile-mixed phosphate buffer (pH 2.6; 10mM) (40:12:48, v/v/v) with a flow rate of 1.2 ml/min.",High-performance liquid chromatographic method for the determination of pioglitazone in human plasma using ultraviolet detection and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815107/),[ml] / [min],1.2,70588,DB01132,Pioglitazone
,26195223,kinact,"We estimated the kinact and K'app values, which are the maximum inactivation rate constant and the apparent dissociation constant, of gemfibrozil to be 0.071 min(-1) and 57.3 μM, respectively.",Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195223/),1/[min],0.071,70604,DB01132,Pioglitazone
,26195223,K'app,"We estimated the kinact and K'app values, which are the maximum inactivation rate constant and the apparent dissociation constant, of gemfibrozil to be 0.071 min(-1) and 57.3 μM, respectively.",Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195223/),1/[min],0.071,70605,DB01132,Pioglitazone
,26195223,maximum inactivation rate constant,"We estimated the kinact and K'app values, which are the maximum inactivation rate constant and the apparent dissociation constant, of gemfibrozil to be 0.071 min(-1) and 57.3 μM, respectively.",Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195223/),1/[min],0.071,70606,DB01132,Pioglitazone
,26195223,apparent dissociation constant,"We estimated the kinact and K'app values, which are the maximum inactivation rate constant and the apparent dissociation constant, of gemfibrozil to be 0.071 min(-1) and 57.3 μM, respectively.",Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195223/),μM,57.3,70607,DB01132,Pioglitazone
,26195223,kobs,"The kobs, in vivo values of potent mechanism-based inhibitors, clarithromycin and erythromycin, were estimated to be 0.0096 min(-1) and 0.0051 min(-1), respectively.",Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195223/),1/[min],0.0096,70608,DB01132,Pioglitazone
,26195223,kobs,"The kobs, in vivo values of potent mechanism-based inhibitors, clarithromycin and erythromycin, were estimated to be 0.0096 min(-1) and 0.0051 min(-1), respectively.",Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195223/),1/[min],0.0051,70609,DB01132,Pioglitazone
,26195223,kobs,"The kobs, in vivo value of gemfibrozil was 0.0060 min(-1), which was comparable to those of clarithromycin and erythromycin, suggesting that gemfibrozil could be a mechanism-based inhibitor as potent as clarithromycin and erythromycin in vivo.",Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195223/),1/[min],0.0060,70610,DB01132,Pioglitazone
,11594240,absolute bioavailability,"It is well-absorbed, with a mean absolute bioavailability of 83% and reaching maximum concentrations in around 1.5 hours.",Pharmacokinetics and clinical efficacy of pioglitazone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11594240/),%,83,72504,DB01132,Pioglitazone
,11594240,half-life,The half-life is about 9 hours but two active metabolites mainly contribute to the extended glucose-lowering effects.,Pharmacokinetics and clinical efficacy of pioglitazone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11594240/),h,9,72505,DB01132,Pioglitazone
,12680885,area under the concentration-time curve (AUC),"After single oral doses, mean area under the concentration-time curve (AUC) values were decreased in patients with severe renal impairment compared with healthy subjects with normal renal function for pioglitazone (13 476 vs 17 387, P = 0.371; -23%; confidence interval (CI) -57, 38), M-III metabolite (13 394 vs 15 071, P = 0.841; -11%; CI -74, 194) and M-IV metabolite (27 991 vs 49 856, P = 0.006; -44%; CI -62, -17).",The pharmacokinetics of pioglitazone in patients with impaired renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12680885/),,13,89199,DB01132,Pioglitazone
,12680885,area under the concentration-time curve (AUC),"After single oral doses, mean area under the concentration-time curve (AUC) values were decreased in patients with severe renal impairment compared with healthy subjects with normal renal function for pioglitazone (13 476 vs 17 387, P = 0.371; -23%; confidence interval (CI) -57, 38), M-III metabolite (13 394 vs 15 071, P = 0.841; -11%; CI -74, 194) and M-IV metabolite (27 991 vs 49 856, P = 0.006; -44%; CI -62, -17).",The pharmacokinetics of pioglitazone in patients with impaired renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12680885/),,17,89200,DB01132,Pioglitazone
,24835512,flow rate,"Liquid-liquid extraction was carried out on 0.2 mL of human plasma using ethyl acetate, and chromatographic separation was performed on an Agilent Eclipse plus C18 column (4.6 mm × 100 mm, 3.5 μm) using a mobile phase consisting of methanol-water-formic acid (95:5:0.1, v/v/v, plus 5mM ammonium acetate) at a flow rate of 0.8 mL/min.",Simultaneous determination of glimepiride and pioglitazone in human plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24835512/),[ml] / [min],0.8,94507,DB01132,Pioglitazone
,24835512,total run time,The total run time was 3.0 min and the elution time was about 2.4 min.,Simultaneous determination of glimepiride and pioglitazone in human plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24835512/),min,3.0,94508,DB01132,Pioglitazone
,24835512,elution time,The total run time was 3.0 min and the elution time was about 2.4 min.,Simultaneous determination of glimepiride and pioglitazone in human plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24835512/),min,2.4,94509,DB01132,Pioglitazone
,23675103,detection limit,"The detection limit is 8.08 × 10(-9) M (3.17 ng ml(-1)) using 300 s pre-concentration time, whereas the quantitative limit is 2.45 × 10(-8) M (9.63 ng ml(-1)).",A Validated Adsorptive Stripping Voltammetric Determination of Antidiabetic Agent Pioglitazone HCl in Tablets and Biological Fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23675103/),M,8.08 × 10(-9),94622,DB01132,Pioglitazone
,23675103,detection limit,"The detection limit is 8.08 × 10(-9) M (3.17 ng ml(-1)) using 300 s pre-concentration time, whereas the quantitative limit is 2.45 × 10(-8) M (9.63 ng ml(-1)).",A Validated Adsorptive Stripping Voltammetric Determination of Antidiabetic Agent Pioglitazone HCl in Tablets and Biological Fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23675103/),[ng] / [ml],3.17,94623,DB01132,Pioglitazone
,23675103,quantitative limit,"The detection limit is 8.08 × 10(-9) M (3.17 ng ml(-1)) using 300 s pre-concentration time, whereas the quantitative limit is 2.45 × 10(-8) M (9.63 ng ml(-1)).",A Validated Adsorptive Stripping Voltammetric Determination of Antidiabetic Agent Pioglitazone HCl in Tablets and Biological Fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23675103/),M,2.45 × 10(-8),94624,DB01132,Pioglitazone
,23675103,quantitative limit,"The detection limit is 8.08 × 10(-9) M (3.17 ng ml(-1)) using 300 s pre-concentration time, whereas the quantitative limit is 2.45 × 10(-8) M (9.63 ng ml(-1)).",A Validated Adsorptive Stripping Voltammetric Determination of Antidiabetic Agent Pioglitazone HCl in Tablets and Biological Fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23675103/),[ng] / [ml],9.63,94625,DB01132,Pioglitazone
,23675103,C max,"The pharmacokinetic parameters of drug in human plasma were estimated as: C max=785.8 ng ml(-1), t max=1.5 h, K e=0.125 h(-1) and t 1/2=8 h which are favorably compared with those reported in literature.",A Validated Adsorptive Stripping Voltammetric Determination of Antidiabetic Agent Pioglitazone HCl in Tablets and Biological Fluids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23675103/),[ng] / [ml],785.8,94626,DB01132,Pioglitazone
,23675103,t max,"The pharmacokinetic parameters of drug in human plasma were estimated as: C max=785.8 ng ml(-1), t max=1.5 h, K e=0.125 h(-1) and t 1/2=8 h which are favorably compared with those reported in literature.",A Validated Adsorptive Stripping Voltammetric Determination of Antidiabetic Agent Pioglitazone HCl in Tablets and Biological Fluids. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23675103/),h,1.5,94627,DB01132,Pioglitazone
,23675103,K e,"The pharmacokinetic parameters of drug in human plasma were estimated as: C max=785.8 ng ml(-1), t max=1.5 h, K e=0.125 h(-1) and t 1/2=8 h which are favorably compared with those reported in literature.",A Validated Adsorptive Stripping Voltammetric Determination of Antidiabetic Agent Pioglitazone HCl in Tablets and Biological Fluids. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23675103/),1/[h],0.125,94628,DB01132,Pioglitazone
,23675103,t 1/2,"The pharmacokinetic parameters of drug in human plasma were estimated as: C max=785.8 ng ml(-1), t max=1.5 h, K e=0.125 h(-1) and t 1/2=8 h which are favorably compared with those reported in literature.",A Validated Adsorptive Stripping Voltammetric Determination of Antidiabetic Agent Pioglitazone HCl in Tablets and Biological Fluids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23675103/),h,8,94629,DB01132,Pioglitazone
,17635496,area under the plasma rosiglitazone concentration-time curve from time 0 to infinity (AUC(0-infinity)),"The mean +/- SD area under the plasma rosiglitazone concentration-time curve from time 0 to infinity (AUC(0-infinity)) was 2024 +/- 561 ng ml(-1) h in the c.521TT subjects, 1763 +/- 288 ng ml(-1) h in the c.521TC subjects (geometric mean ratio c.521TC/c.521TT 0.89; 95% confidence interval 0.72, 1.11) and 1729 +/- 346 ng ml(-1) h in the c.521CC subjects (c.521CC/c.521TT 0.87; 0.63, 1.20).",No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17635496/),[h·ng] / [ml],2024,100947,DB01132,Pioglitazone
,17635496,area under the plasma rosiglitazone concentration-time curve from time 0 to infinity (AUC(0-infinity)),"The mean +/- SD area under the plasma rosiglitazone concentration-time curve from time 0 to infinity (AUC(0-infinity)) was 2024 +/- 561 ng ml(-1) h in the c.521TT subjects, 1763 +/- 288 ng ml(-1) h in the c.521TC subjects (geometric mean ratio c.521TC/c.521TT 0.89; 95% confidence interval 0.72, 1.11) and 1729 +/- 346 ng ml(-1) h in the c.521CC subjects (c.521CC/c.521TT 0.87; 0.63, 1.20).",No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17635496/),[h·ng] / [ml],1763,100948,DB01132,Pioglitazone
,17635496,area under the plasma rosiglitazone concentration-time curve from time 0 to infinity (AUC(0-infinity)),"The mean +/- SD area under the plasma rosiglitazone concentration-time curve from time 0 to infinity (AUC(0-infinity)) was 2024 +/- 561 ng ml(-1) h in the c.521TT subjects, 1763 +/- 288 ng ml(-1) h in the c.521TC subjects (geometric mean ratio c.521TC/c.521TT 0.89; 95% confidence interval 0.72, 1.11) and 1729 +/- 346 ng ml(-1) h in the c.521CC subjects (c.521CC/c.521TT 0.87; 0.63, 1.20).",No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17635496/),[h·ng] / [ml],1729,100949,DB01132,Pioglitazone
,17635496,AUC(0-infinity),"The AUC(0-infinity) of pioglitazone averaged 6244 +/- 1909 ng ml(-1) h in the c.521TT subjects, 5123 +/- 1165 ng ml(-1) h in the c.521TC subjects (c.521TC/c.521TT 0.83; 0.65, 1.06) and 4851 +/- 1123 ng ml(-1) h in the c.521CC subjects (c.521CC/c.521TT 0.79; 0.55, 1.14).",No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17635496/),[h·ng] / [ml],6244,100950,DB01132,Pioglitazone
,17635496,AUC(0-infinity),"The AUC(0-infinity) of pioglitazone averaged 6244 +/- 1909 ng ml(-1) h in the c.521TT subjects, 5123 +/- 1165 ng ml(-1) h in the c.521TC subjects (c.521TC/c.521TT 0.83; 0.65, 1.06) and 4851 +/- 1123 ng ml(-1) h in the c.521CC subjects (c.521CC/c.521TT 0.79; 0.55, 1.14).",No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17635496/),[h·ng] / [ml],5123,100951,DB01132,Pioglitazone
,17635496,AUC(0-infinity),"The AUC(0-infinity) of pioglitazone averaged 6244 +/- 1909 ng ml(-1) h in the c.521TT subjects, 5123 +/- 1165 ng ml(-1) h in the c.521TC subjects (c.521TC/c.521TT 0.83; 0.65, 1.06) and 4851 +/- 1123 ng ml(-1) h in the c.521CC subjects (c.521CC/c.521TT 0.79; 0.55, 1.14).",No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17635496/),[h·ng] / [ml],4851,100952,DB01132,Pioglitazone
,18677971,flow rate,The mobile phase consisting of acetonitrile:potassium di-hydrogen phosphate buffer (35:65 v/v) was used at the flow rate of 1.2 ml/min on a reverse phase C18 column.,"Validated high performance liquid chromatographic method for simultaneous determination of rosiglitazone, cilostazol, and 3,4-dehydro-cilostazol in rat plasma and its application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677971/),[ml] / [min],1.2,114108,DB01132,Pioglitazone
above,18677971,absolute recovery,The absolute recovery was above 90% of all analytes over the concentration range of 25-2500 ng/ml for RSG and CLZ and 20-2000 ng/ ml for DCLZ.,"Validated high performance liquid chromatographic method for simultaneous determination of rosiglitazone, cilostazol, and 3,4-dehydro-cilostazol in rat plasma and its application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677971/),%,90,114109,DB01132,Pioglitazone
,18677971,absolute recovery,The absolute recovery was above 90% of all analytes over the concentration range of 25-2500 ng/ml for RSG and CLZ and 20-2000 ng/ ml for DCLZ.,"Validated high performance liquid chromatographic method for simultaneous determination of rosiglitazone, cilostazol, and 3,4-dehydro-cilostazol in rat plasma and its application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677971/),[ng] / [ml],20-2000,114110,DB01132,Pioglitazone
,15497670,Cmax,"The mean Cmax of pioglitazone ranged between 1.01 microg/mL and 1.05 microg/mL, while the mean AUC0-inf and AUC0-t ranged between 10.89 microg x h/mL and 10.98 microg x h/mL as well as between 10.56 microg x h/mL and 10.62 microg x h/mL for the test and reference formulations, respectively.",In vivo bioequivalence of oral antidiabetic agents: pioglitazone tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497670/),[μg] / [ml],1.01,117053,DB01132,Pioglitazone
,15497670,Cmax,"The mean Cmax of pioglitazone ranged between 1.01 microg/mL and 1.05 microg/mL, while the mean AUC0-inf and AUC0-t ranged between 10.89 microg x h/mL and 10.98 microg x h/mL as well as between 10.56 microg x h/mL and 10.62 microg x h/mL for the test and reference formulations, respectively.",In vivo bioequivalence of oral antidiabetic agents: pioglitazone tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497670/),[μg] / [ml],1.05,117054,DB01132,Pioglitazone
,15497670,AUC0-inf,"The mean Cmax of pioglitazone ranged between 1.01 microg/mL and 1.05 microg/mL, while the mean AUC0-inf and AUC0-t ranged between 10.89 microg x h/mL and 10.98 microg x h/mL as well as between 10.56 microg x h/mL and 10.62 microg x h/mL for the test and reference formulations, respectively.",In vivo bioequivalence of oral antidiabetic agents: pioglitazone tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497670/),[h·μg] / [ml],10.89,117055,DB01132,Pioglitazone
,15497670,AUC0-inf,"The mean Cmax of pioglitazone ranged between 1.01 microg/mL and 1.05 microg/mL, while the mean AUC0-inf and AUC0-t ranged between 10.89 microg x h/mL and 10.98 microg x h/mL as well as between 10.56 microg x h/mL and 10.62 microg x h/mL for the test and reference formulations, respectively.",In vivo bioequivalence of oral antidiabetic agents: pioglitazone tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497670/),[h·μg] / [ml],10.56,117056,DB01132,Pioglitazone
,15497670,AUC0-t,"The mean Cmax of pioglitazone ranged between 1.01 microg/mL and 1.05 microg/mL, while the mean AUC0-inf and AUC0-t ranged between 10.89 microg x h/mL and 10.98 microg x h/mL as well as between 10.56 microg x h/mL and 10.62 microg x h/mL for the test and reference formulations, respectively.",In vivo bioequivalence of oral antidiabetic agents: pioglitazone tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497670/),[h·μg] / [ml],10.98,117057,DB01132,Pioglitazone
,15497670,AUC0-t,"The mean Cmax of pioglitazone ranged between 1.01 microg/mL and 1.05 microg/mL, while the mean AUC0-inf and AUC0-t ranged between 10.89 microg x h/mL and 10.98 microg x h/mL as well as between 10.56 microg x h/mL and 10.62 microg x h/mL for the test and reference formulations, respectively.",In vivo bioequivalence of oral antidiabetic agents: pioglitazone tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497670/),[h·μg] / [ml],10.56,117058,DB01132,Pioglitazone
,15497670,AUC0-t,"The mean Cmax of pioglitazone ranged between 1.01 microg/mL and 1.05 microg/mL, while the mean AUC0-inf and AUC0-t ranged between 10.89 microg x h/mL and 10.98 microg x h/mL as well as between 10.56 microg x h/mL and 10.62 microg x h/mL for the test and reference formulations, respectively.",In vivo bioequivalence of oral antidiabetic agents: pioglitazone tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497670/),[h·μg] / [ml],10.62,117059,DB01132,Pioglitazone
,15497670,Tmax,The median Tmax for the test tablets was 1.50 h and for the reference was 1.75 h.,In vivo bioequivalence of oral antidiabetic agents: pioglitazone tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497670/),h,1.50,117060,DB01132,Pioglitazone
,15497670,Tmax,The median Tmax for the test tablets was 1.50 h and for the reference was 1.75 h.,In vivo bioequivalence of oral antidiabetic agents: pioglitazone tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497670/),h,1.75,117061,DB01132,Pioglitazone
,25316572,urinary excretion,"Although urinary excretion of ipragliflozin is low (approximately 1 %), tubular concentration of free ipragliflozin is adequate to provide pharmacological activities.",Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25316572/),%,1,120234,DB01132,Pioglitazone
,21351826,peak detachment force,"Formulation (PF6) showed peak detachment force (3.12 N), work of adhesion (0.72 mJ), swelling index (196%), erosion (10.8%), in vivo residence time of 280 min, in vitro drug release (99.65% and 98.96% in 6 h for FDP and PIO, respectively) with higuchi model release profile and permeated 66.1 and 64.6 % with a flux of 0.118 and 0.331 mg/h/cm(2) of FDP and PIO through porcine buccal membrane.","Development of bioadhesive buccal tablets for felodipine and pioglitazone in combined dosage form: in vitro, ex vivo, and in vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351826/),n,3.12,120907,DB01132,Pioglitazone
,21351826,work of adhesion,"Formulation (PF6) showed peak detachment force (3.12 N), work of adhesion (0.72 mJ), swelling index (196%), erosion (10.8%), in vivo residence time of 280 min, in vitro drug release (99.65% and 98.96% in 6 h for FDP and PIO, respectively) with higuchi model release profile and permeated 66.1 and 64.6 % with a flux of 0.118 and 0.331 mg/h/cm(2) of FDP and PIO through porcine buccal membrane.","Development of bioadhesive buccal tablets for felodipine and pioglitazone in combined dosage form: in vitro, ex vivo, and in vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351826/),mj,0.72,120908,DB01132,Pioglitazone
,21351826,flux,"Formulation (PF6) showed peak detachment force (3.12 N), work of adhesion (0.72 mJ), swelling index (196%), erosion (10.8%), in vivo residence time of 280 min, in vitro drug release (99.65% and 98.96% in 6 h for FDP and PIO, respectively) with higuchi model release profile and permeated 66.1 and 64.6 % with a flux of 0.118 and 0.331 mg/h/cm(2) of FDP and PIO through porcine buccal membrane.","Development of bioadhesive buccal tablets for felodipine and pioglitazone in combined dosage form: in vitro, ex vivo, and in vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351826/),[h·mg] / [cm(2],0.118,120909,DB01132,Pioglitazone
,21351826,flux,"Formulation (PF6) showed peak detachment force (3.12 N), work of adhesion (0.72 mJ), swelling index (196%), erosion (10.8%), in vivo residence time of 280 min, in vitro drug release (99.65% and 98.96% in 6 h for FDP and PIO, respectively) with higuchi model release profile and permeated 66.1 and 64.6 % with a flux of 0.118 and 0.331 mg/h/cm(2) of FDP and PIO through porcine buccal membrane.","Development of bioadhesive buccal tablets for felodipine and pioglitazone in combined dosage form: in vitro, ex vivo, and in vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351826/),[h·mg] / [cm(2],0.331,120910,DB01132,Pioglitazone
,22339447,absolute bioavailability,"Following oral administration, vildagliptin is rapidly and well absorbed with an absolute bioavailability of 85%.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),%,85,128972,DB01132,Pioglitazone
,22339447,volume of distribution,"Vildagliptin is minimally bound to plasma proteins (9.3%) and, on the basis of a volume of distribution of 71 L, it is considered to distribute extensively into extravascular spaces.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),l,71,128973,DB01132,Pioglitazone
,22339447,Renal clearance,Renal clearance of vildagliptin (13 L/h) accounts for 33% of the total body clearance after intravenous administration (41 L/h).,Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[l] / [h],13,128974,DB01132,Pioglitazone
,22339447,total body clearance,Renal clearance of vildagliptin (13 L/h) accounts for 33% of the total body clearance after intravenous administration (41 L/h).,Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[l] / [h],41,128975,DB01132,Pioglitazone
,22339447,IC(50)),"Vildagliptin is a potent inhibitor of the DPP-4 enzyme, with a concentration required to achieve 50% DPP-4 inhibition (IC(50)) of 4.5 nmol/L in patients with T2DM.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[nM] / [l],4.5,128976,DB01132,Pioglitazone
,25972738,Cmax,"Cmax, the mean peak plasma concentration was 4.33 ± 2.4 μg/mL versus 4.76 ± 2.1 μg/ml, tmax, time taken to reach, was 2.91 ± 1.11 h versus 3.6 ± 1.83 h, total area under the curve AUC0-t was 64.90 ± 43.6 μg·h/ml versus 102.90 ± 66.9 μg·h/ml, AUC0-∞ was 74.0 ± 52.6 μg·h/ml versus 124.3 ± 85 μg·h/mL, t ½ was 14.10 ± 2.5 h versus 16.43 ± 6.43 h and elimination rate constant ke was 0.050 ± 0.009 h(-1) versus 0.057 ± 0.049 h(-1), respectively.",The effect of pioglitazone on pharmacokinetics of carbamazepine in healthy rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25972738/),[μg] / [ml],4.33,131119,DB01132,Pioglitazone
,25972738,Cmax,"Cmax, the mean peak plasma concentration was 4.33 ± 2.4 μg/mL versus 4.76 ± 2.1 μg/ml, tmax, time taken to reach, was 2.91 ± 1.11 h versus 3.6 ± 1.83 h, total area under the curve AUC0-t was 64.90 ± 43.6 μg·h/ml versus 102.90 ± 66.9 μg·h/ml, AUC0-∞ was 74.0 ± 52.6 μg·h/ml versus 124.3 ± 85 μg·h/mL, t ½ was 14.10 ± 2.5 h versus 16.43 ± 6.43 h and elimination rate constant ke was 0.050 ± 0.009 h(-1) versus 0.057 ± 0.049 h(-1), respectively.",The effect of pioglitazone on pharmacokinetics of carbamazepine in healthy rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25972738/),[μg] / [ml],4.76,131120,DB01132,Pioglitazone
,25972738,tmax,"Cmax, the mean peak plasma concentration was 4.33 ± 2.4 μg/mL versus 4.76 ± 2.1 μg/ml, tmax, time taken to reach, was 2.91 ± 1.11 h versus 3.6 ± 1.83 h, total area under the curve AUC0-t was 64.90 ± 43.6 μg·h/ml versus 102.90 ± 66.9 μg·h/ml, AUC0-∞ was 74.0 ± 52.6 μg·h/ml versus 124.3 ± 85 μg·h/mL, t ½ was 14.10 ± 2.5 h versus 16.43 ± 6.43 h and elimination rate constant ke was 0.050 ± 0.009 h(-1) versus 0.057 ± 0.049 h(-1), respectively.",The effect of pioglitazone on pharmacokinetics of carbamazepine in healthy rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25972738/),h,2.91,131121,DB01132,Pioglitazone
,25972738,tmax,"Cmax, the mean peak plasma concentration was 4.33 ± 2.4 μg/mL versus 4.76 ± 2.1 μg/ml, tmax, time taken to reach, was 2.91 ± 1.11 h versus 3.6 ± 1.83 h, total area under the curve AUC0-t was 64.90 ± 43.6 μg·h/ml versus 102.90 ± 66.9 μg·h/ml, AUC0-∞ was 74.0 ± 52.6 μg·h/ml versus 124.3 ± 85 μg·h/mL, t ½ was 14.10 ± 2.5 h versus 16.43 ± 6.43 h and elimination rate constant ke was 0.050 ± 0.009 h(-1) versus 0.057 ± 0.049 h(-1), respectively.",The effect of pioglitazone on pharmacokinetics of carbamazepine in healthy rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25972738/),h,3.6,131122,DB01132,Pioglitazone
,25972738,total area under the curve AUC0-t,"Cmax, the mean peak plasma concentration was 4.33 ± 2.4 μg/mL versus 4.76 ± 2.1 μg/ml, tmax, time taken to reach, was 2.91 ± 1.11 h versus 3.6 ± 1.83 h, total area under the curve AUC0-t was 64.90 ± 43.6 μg·h/ml versus 102.90 ± 66.9 μg·h/ml, AUC0-∞ was 74.0 ± 52.6 μg·h/ml versus 124.3 ± 85 μg·h/mL, t ½ was 14.10 ± 2.5 h versus 16.43 ± 6.43 h and elimination rate constant ke was 0.050 ± 0.009 h(-1) versus 0.057 ± 0.049 h(-1), respectively.",The effect of pioglitazone on pharmacokinetics of carbamazepine in healthy rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25972738/),[h·μg] / [ml],64.90,131123,DB01132,Pioglitazone
,25972738,total area under the curve AUC0-t,"Cmax, the mean peak plasma concentration was 4.33 ± 2.4 μg/mL versus 4.76 ± 2.1 μg/ml, tmax, time taken to reach, was 2.91 ± 1.11 h versus 3.6 ± 1.83 h, total area under the curve AUC0-t was 64.90 ± 43.6 μg·h/ml versus 102.90 ± 66.9 μg·h/ml, AUC0-∞ was 74.0 ± 52.6 μg·h/ml versus 124.3 ± 85 μg·h/mL, t ½ was 14.10 ± 2.5 h versus 16.43 ± 6.43 h and elimination rate constant ke was 0.050 ± 0.009 h(-1) versus 0.057 ± 0.049 h(-1), respectively.",The effect of pioglitazone on pharmacokinetics of carbamazepine in healthy rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25972738/),[h·μg] / [ml],102.90,131124,DB01132,Pioglitazone
,25972738,AUC0-∞,"Cmax, the mean peak plasma concentration was 4.33 ± 2.4 μg/mL versus 4.76 ± 2.1 μg/ml, tmax, time taken to reach, was 2.91 ± 1.11 h versus 3.6 ± 1.83 h, total area under the curve AUC0-t was 64.90 ± 43.6 μg·h/ml versus 102.90 ± 66.9 μg·h/ml, AUC0-∞ was 74.0 ± 52.6 μg·h/ml versus 124.3 ± 85 μg·h/mL, t ½ was 14.10 ± 2.5 h versus 16.43 ± 6.43 h and elimination rate constant ke was 0.050 ± 0.009 h(-1) versus 0.057 ± 0.049 h(-1), respectively.",The effect of pioglitazone on pharmacokinetics of carbamazepine in healthy rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25972738/),[h·μg] / [ml],74.0,131125,DB01132,Pioglitazone
,25972738,AUC0-∞,"Cmax, the mean peak plasma concentration was 4.33 ± 2.4 μg/mL versus 4.76 ± 2.1 μg/ml, tmax, time taken to reach, was 2.91 ± 1.11 h versus 3.6 ± 1.83 h, total area under the curve AUC0-t was 64.90 ± 43.6 μg·h/ml versus 102.90 ± 66.9 μg·h/ml, AUC0-∞ was 74.0 ± 52.6 μg·h/ml versus 124.3 ± 85 μg·h/mL, t ½ was 14.10 ± 2.5 h versus 16.43 ± 6.43 h and elimination rate constant ke was 0.050 ± 0.009 h(-1) versus 0.057 ± 0.049 h(-1), respectively.",The effect of pioglitazone on pharmacokinetics of carbamazepine in healthy rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25972738/),[h·μg] / [ml],124.3,131126,DB01132,Pioglitazone
,25972738,t ½,"Cmax, the mean peak plasma concentration was 4.33 ± 2.4 μg/mL versus 4.76 ± 2.1 μg/ml, tmax, time taken to reach, was 2.91 ± 1.11 h versus 3.6 ± 1.83 h, total area under the curve AUC0-t was 64.90 ± 43.6 μg·h/ml versus 102.90 ± 66.9 μg·h/ml, AUC0-∞ was 74.0 ± 52.6 μg·h/ml versus 124.3 ± 85 μg·h/mL, t ½ was 14.10 ± 2.5 h versus 16.43 ± 6.43 h and elimination rate constant ke was 0.050 ± 0.009 h(-1) versus 0.057 ± 0.049 h(-1), respectively.",The effect of pioglitazone on pharmacokinetics of carbamazepine in healthy rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25972738/),h,14.10,131127,DB01132,Pioglitazone
,25972738,t ½,"Cmax, the mean peak plasma concentration was 4.33 ± 2.4 μg/mL versus 4.76 ± 2.1 μg/ml, tmax, time taken to reach, was 2.91 ± 1.11 h versus 3.6 ± 1.83 h, total area under the curve AUC0-t was 64.90 ± 43.6 μg·h/ml versus 102.90 ± 66.9 μg·h/ml, AUC0-∞ was 74.0 ± 52.6 μg·h/ml versus 124.3 ± 85 μg·h/mL, t ½ was 14.10 ± 2.5 h versus 16.43 ± 6.43 h and elimination rate constant ke was 0.050 ± 0.009 h(-1) versus 0.057 ± 0.049 h(-1), respectively.",The effect of pioglitazone on pharmacokinetics of carbamazepine in healthy rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25972738/),h,16.43,131128,DB01132,Pioglitazone
,25972738,elimination rate constant ke,"Cmax, the mean peak plasma concentration was 4.33 ± 2.4 μg/mL versus 4.76 ± 2.1 μg/ml, tmax, time taken to reach, was 2.91 ± 1.11 h versus 3.6 ± 1.83 h, total area under the curve AUC0-t was 64.90 ± 43.6 μg·h/ml versus 102.90 ± 66.9 μg·h/ml, AUC0-∞ was 74.0 ± 52.6 μg·h/ml versus 124.3 ± 85 μg·h/mL, t ½ was 14.10 ± 2.5 h versus 16.43 ± 6.43 h and elimination rate constant ke was 0.050 ± 0.009 h(-1) versus 0.057 ± 0.049 h(-1), respectively.",The effect of pioglitazone on pharmacokinetics of carbamazepine in healthy rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25972738/),1/[h],0.050,131129,DB01132,Pioglitazone
,25972738,elimination rate constant ke,"Cmax, the mean peak plasma concentration was 4.33 ± 2.4 μg/mL versus 4.76 ± 2.1 μg/ml, tmax, time taken to reach, was 2.91 ± 1.11 h versus 3.6 ± 1.83 h, total area under the curve AUC0-t was 64.90 ± 43.6 μg·h/ml versus 102.90 ± 66.9 μg·h/ml, AUC0-∞ was 74.0 ± 52.6 μg·h/ml versus 124.3 ± 85 μg·h/mL, t ½ was 14.10 ± 2.5 h versus 16.43 ± 6.43 h and elimination rate constant ke was 0.050 ± 0.009 h(-1) versus 0.057 ± 0.049 h(-1), respectively.",The effect of pioglitazone on pharmacokinetics of carbamazepine in healthy rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25972738/),1/[h],0.057,131130,DB01132,Pioglitazone
,9037440,Cmax,"In rats, the concentration of pioglitazone in plasma reached a peak (Cmax 0.71 micrograms/ml) at 4 h (tmax) after dosing and declined with a half-life (t1/2) of 2.6 h.","Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9037440/),[μg] / [ml],0.71,138681,DB01132,Pioglitazone
,9037440,half-life (t1/2),"In rats, the concentration of pioglitazone in plasma reached a peak (Cmax 0.71 micrograms/ml) at 4 h (tmax) after dosing and declined with a half-life (t1/2) of 2.6 h.","Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9037440/),h,2.6,138682,DB01132,Pioglitazone
,9037440,tmax,"In dogs, tmax, Cmax and t1/2 were 0.5 h 0.32 micrograms/ml and 2.1 h, and those for monkeys were 4.3 h, 0.43 micrograms/ml and 5.3 h, respectively.","Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9037440/),h,0.5,138683,DB01132,Pioglitazone
,9037440,tmax,"In dogs, tmax, Cmax and t1/2 were 0.5 h 0.32 micrograms/ml and 2.1 h, and those for monkeys were 4.3 h, 0.43 micrograms/ml and 5.3 h, respectively.","Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9037440/),h,4.3,138684,DB01132,Pioglitazone
,9037440,Cmax,"In dogs, tmax, Cmax and t1/2 were 0.5 h 0.32 micrograms/ml and 2.1 h, and those for monkeys were 4.3 h, 0.43 micrograms/ml and 5.3 h, respectively.","Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9037440/),[μg] / [ml],0.32,138685,DB01132,Pioglitazone
,9037440,Cmax,"In dogs, tmax, Cmax and t1/2 were 0.5 h 0.32 micrograms/ml and 2.1 h, and those for monkeys were 4.3 h, 0.43 micrograms/ml and 5.3 h, respectively.","Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9037440/),h,2.1,138686,DB01132,Pioglitazone
,9037440,Cmax,"In dogs, tmax, Cmax and t1/2 were 0.5 h 0.32 micrograms/ml and 2.1 h, and those for monkeys were 4.3 h, 0.43 micrograms/ml and 5.3 h, respectively.","Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9037440/),h,4.3,138687,DB01132,Pioglitazone
,9037440,Cmax,"In dogs, tmax, Cmax and t1/2 were 0.5 h 0.32 micrograms/ml and 2.1 h, and those for monkeys were 4.3 h, 0.43 micrograms/ml and 5.3 h, respectively.","Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9037440/),[μg] / [ml],0.43,138688,DB01132,Pioglitazone
,9037440,t1/2,"In dogs, tmax, Cmax and t1/2 were 0.5 h 0.32 micrograms/ml and 2.1 h, and those for monkeys were 4.3 h, 0.43 micrograms/ml and 5.3 h, respectively.","Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9037440/),h,2.1,138689,DB01132,Pioglitazone
,9037440,t1/2,"In dogs, tmax, Cmax and t1/2 were 0.5 h 0.32 micrograms/ml and 2.1 h, and those for monkeys were 4.3 h, 0.43 micrograms/ml and 5.3 h, respectively.","Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9037440/),h,5.3,138690,DB01132,Pioglitazone
below,25157965,solubility,"All PIO derivatives prepared are crystalline solids as determined by powder X-ray diffraction, and the solubility in aqueous media is below 1 μM at 37 °C.",Prodrugs of pioglitazone for extended-release (XR) injectable formulations. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25157965/),μM,1,147132,DB01132,Pioglitazone
,25157965,melting points,"The melting points steadily increase from 55 °C, for the hexanoyloxymethyl derivative, to 85 °C, for the palmitoyloxymethyl derivative; inversely, the solubilities in ethyl oleate decrease as a function of increasing acyl chain length.",Prodrugs of pioglitazone for extended-release (XR) injectable formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25157965/),°c,55,147133,DB01132,Pioglitazone
,25157965,melting points,"The melting points steadily increase from 55 °C, for the hexanoyloxymethyl derivative, to 85 °C, for the palmitoyloxymethyl derivative; inversely, the solubilities in ethyl oleate decrease as a function of increasing acyl chain length.",Prodrugs of pioglitazone for extended-release (XR) injectable formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25157965/),°c,85,147134,DB01132,Pioglitazone
<,25157965,half-life,"The butyroyloxymethyl derivative is efficiently converted to PIO in in vitro rat plasma with a half-life of <2 min at 37 (o) C, while the rate of enzymatic cleavage in rat plasma decreases as the ester chain length increases for the longer acyloxymethyl derivatives.",Prodrugs of pioglitazone for extended-release (XR) injectable formulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25157965/),min,2,147135,DB01132,Pioglitazone
,21492190,maximum plasma concentration,"The maximum plasma concentration was 509.1 ± 413.5 ng/mL achieved at 1.88 ± 1.39 h following oral administration of the first dose, and 448.1 ± 303.5 ng/mL achieved at 2.83 ± 1.81 h (mean ± SD) following the eleventh dose.",Pharmacokinetics of pioglitazone after multiple oral dose administration in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492190/),[ng] / [ml],509.1,148916,DB01132,Pioglitazone
,21492190,maximum plasma concentration,"The maximum plasma concentration was 509.1 ± 413.5 ng/mL achieved at 1.88 ± 1.39 h following oral administration of the first dose, and 448.1 ± 303.5 ng/mL achieved at 2.83 ± 1.81 h (mean ± SD) following the eleventh dose.",Pharmacokinetics of pioglitazone after multiple oral dose administration in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492190/),[ng] / [ml],448.1,148917,DB01132,Pioglitazone
,21492190,Apparent elimination half-life,"Apparent elimination half-life was 9.94 ± 4.57 and 9.63 ± 5.33 h after the first and eleventh dose, respectively.",Pharmacokinetics of pioglitazone after multiple oral dose administration in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492190/),h,9.94,148918,DB01132,Pioglitazone
,21492190,Apparent elimination half-life,"Apparent elimination half-life was 9.94 ± 4.57 and 9.63 ± 5.33 h after the first and eleventh dose, respectively.",Pharmacokinetics of pioglitazone after multiple oral dose administration in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492190/),h,9.63,148919,DB01132,Pioglitazone
,16447051,peak time,"Also the half-life of repaglinide was unaffected, but the median peak time of repaglinide was shortened from 40 min to 20 min by pioglitazone (P=0.014).","Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16447051/),min,40,149586,DB01132,Pioglitazone
,16447051,peak time,"Also the half-life of repaglinide was unaffected, but the median peak time of repaglinide was shortened from 40 min to 20 min by pioglitazone (P=0.014).","Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16447051/),min,20,149587,DB01132,Pioglitazone
,27504016,IC50,"Abiraterone acetate and abiraterone and its major metabolites, abiraterone sulfate and abiraterone sulfate N-oxide, inhibited CYP2C8 in human liver microsomes, with IC50 values near or below the peak total concentrations observed in patients with metastatic castration-resistant prostate cancer (IC50 values: 1.3-3.0 µM, 1.6-2.9 µM, 0.044-0.15 µM, and 5.4-5.9 µM, respectively).","In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27504016/),μM,1.3-3.0,151300,DB01132,Pioglitazone
,27504016,IC50,"Abiraterone acetate and abiraterone and its major metabolites, abiraterone sulfate and abiraterone sulfate N-oxide, inhibited CYP2C8 in human liver microsomes, with IC50 values near or below the peak total concentrations observed in patients with metastatic castration-resistant prostate cancer (IC50 values: 1.3-3.0 µM, 1.6-2.9 µM, 0.044-0.15 µM, and 5.4-5.9 µM, respectively).","In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27504016/),μM,1.6-2.9,151301,DB01132,Pioglitazone
,27504016,IC50,"Abiraterone acetate and abiraterone and its major metabolites, abiraterone sulfate and abiraterone sulfate N-oxide, inhibited CYP2C8 in human liver microsomes, with IC50 values near or below the peak total concentrations observed in patients with metastatic castration-resistant prostate cancer (IC50 values: 1.3-3.0 µM, 1.6-2.9 µM, 0.044-0.15 µM, and 5.4-5.9 µM, respectively).","In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27504016/),μM,0.044-0.15,151302,DB01132,Pioglitazone
,27504016,IC50,"Abiraterone acetate and abiraterone and its major metabolites, abiraterone sulfate and abiraterone sulfate N-oxide, inhibited CYP2C8 in human liver microsomes, with IC50 values near or below the peak total concentrations observed in patients with metastatic castration-resistant prostate cancer (IC50 values: 1.3-3.0 µM, 1.6-2.9 µM, 0.044-0.15 µM, and 5.4-5.9 µM, respectively).","In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27504016/),μM,5.4-5.9,151303,DB01132,Pioglitazone
,19007483,flow rate,The flow rate was set at 1.4 mL/min.,Development and validation of a simple and rapid HPLC method for determination of pioglitazone in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19007483/),[ml] / [min],1.4,153982,DB01132,Pioglitazone
,19007483,total run time of analysis,Ethylparaben was used as internal standard and the total run time of analysis was approximately 7 min.,Development and validation of a simple and rapid HPLC method for determination of pioglitazone in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19007483/),min,7,153983,DB01132,Pioglitazone
,12463723,ratios,"The mean +/- SD 6-beta-hydroxycortisol/cortisol ratios before and after treatment were 8.3 +/- 4.4 and 9.4 +/- 4.0, respectively (p = 0.29).",Pioglitazone: effect on CYP3A4 activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12463723/),,8.3,157347,DB01132,Pioglitazone
,12463723,ratios,"The mean +/- SD 6-beta-hydroxycortisol/cortisol ratios before and after treatment were 8.3 +/- 4.4 and 9.4 +/- 4.0, respectively (p = 0.29).",Pioglitazone: effect on CYP3A4 activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12463723/),,9.4,157348,DB01132,Pioglitazone
,23712614,AUC0-∞,"Pioglitazone area under the plasma concentration-time curve (AUC)0-∞ and half-life (t1/2 ) did not differ significantly between CYP2C8*1/*1 and CYP2C8*2 carriers (AUC0-∞ 7331 ± 2846 vs 10431 ± 5090 ng*h/ml, p=0.15, t1/2 7.4 ± 2.7 vs 10.5 ± 4.0 h, p=0.07).",Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23712614/),[h·ng] / [ml],7331,166138,DB01132,Pioglitazone
,23712614,AUC0-∞,"Pioglitazone area under the plasma concentration-time curve (AUC)0-∞ and half-life (t1/2 ) did not differ significantly between CYP2C8*1/*1 and CYP2C8*2 carriers (AUC0-∞ 7331 ± 2846 vs 10431 ± 5090 ng*h/ml, p=0.15, t1/2 7.4 ± 2.7 vs 10.5 ± 4.0 h, p=0.07).",Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23712614/),[h·ng] / [ml],10431,166139,DB01132,Pioglitazone
,23712614,t1/2,"Pioglitazone area under the plasma concentration-time curve (AUC)0-∞ and half-life (t1/2 ) did not differ significantly between CYP2C8*1/*1 and CYP2C8*2 carriers (AUC0-∞ 7331 ± 2846 vs 10431 ± 5090 ng*h/ml, p=0.15, t1/2 7.4 ± 2.7 vs 10.5 ± 4.0 h, p=0.07).",Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23712614/),h,7.4,166140,DB01132,Pioglitazone
,23712614,t1/2,"Pioglitazone area under the plasma concentration-time curve (AUC)0-∞ and half-life (t1/2 ) did not differ significantly between CYP2C8*1/*1 and CYP2C8*2 carriers (AUC0-∞ 7331 ± 2846 vs 10431 ± 5090 ng*h/ml, p=0.15, t1/2 7.4 ± 2.7 vs 10.5 ± 4.0 h, p=0.07).",Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23712614/),h,10.5,166141,DB01132,Pioglitazone
,23712614,AUC0-48 ratio,"However, the M-III:pioglitazone AUC0-48 ratio was significantly lower in CYP2C8*2 carriers than CYP2C8*1 homozygotes (0.70 ± 0.15 vs 1.2 ± 0.37, p=0.006).",Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23712614/),,0.70,166142,DB01132,Pioglitazone
,23712614,AUC0-48 ratio,"However, the M-III:pioglitazone AUC0-48 ratio was significantly lower in CYP2C8*2 carriers than CYP2C8*1 homozygotes (0.70 ± 0.15 vs 1.2 ± 0.37, p=0.006).",Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23712614/),,1.2,166143,DB01132,Pioglitazone
,23712614,AUC0-48 ratio,"Similarly, CYP2C8*2 carriers had a significantly lower M-III:M-IV AUC0-48 ratio than participants with the CYP2C8*1/*1 genotype (0.82 ± 0.26 vs 1.22 ± 0.26, p=0.006).",Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23712614/),,0.82,166144,DB01132,Pioglitazone
,23712614,AUC0-48 ratio,"Similarly, CYP2C8*2 carriers had a significantly lower M-III:M-IV AUC0-48 ratio than participants with the CYP2C8*1/*1 genotype (0.82 ± 0.26 vs 1.22 ± 0.26, p=0.006).",Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23712614/),,1.22,166145,DB01132,Pioglitazone
,20629390,retention time,"Under these conditions, the retention time of pioglitazone was 5.2 min.",Rapid HPLC determination of pioglitazone in human plasma by protein precipitation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20629390/),min,5.2,169722,DB01132,Pioglitazone
,20629390,LOQ,The LOQ was 44.2 ng/mL.,Rapid HPLC determination of pioglitazone in human plasma by protein precipitation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20629390/),[ng] / [ml],44.2,169723,DB01132,Pioglitazone
,21355443,extraction recovery,"The mean extraction recovery was found to be 90.2 +/- 4.5, 76.8 +/- 2.8 and 85.2 +/- 5.2% for PIO, GLM and internal standard, respectively.",Novel liquid chromatographic method for simultaneous estimation of pioglitazone and glimepiride in rat plasma by solid phase extraction: application to preclinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355443/),%,90.2,172432,DB01132,Pioglitazone
,21355443,extraction recovery,"The mean extraction recovery was found to be 90.2 +/- 4.5, 76.8 +/- 2.8 and 85.2 +/- 5.2% for PIO, GLM and internal standard, respectively.",Novel liquid chromatographic method for simultaneous estimation of pioglitazone and glimepiride in rat plasma by solid phase extraction: application to preclinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355443/),%,76.8,172433,DB01132,Pioglitazone
,21355443,extraction recovery,"The mean extraction recovery was found to be 90.2 +/- 4.5, 76.8 +/- 2.8 and 85.2 +/- 5.2% for PIO, GLM and internal standard, respectively.",Novel liquid chromatographic method for simultaneous estimation of pioglitazone and glimepiride in rat plasma by solid phase extraction: application to preclinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355443/),%,85.2,172434,DB01132,Pioglitazone
,25668796,flow rate,"Analyses were performed on a liquid chromatography system employing a Kromasil 60-5CN column (2.1 mm × 100 mm, 5 μm) and an isocratic elution with mixed solution of acetonitrile-20mM ammonium formate containing 0.3% formic acid (40:60, v/v), at a flow rate of 0.35 mL/min.",Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25668796/),[ml] / [min],0.35,182760,DB01132,Pioglitazone
,25668796,m/z,"The determination was carried out on an API 4000 triple-quadrupole mass spectrometer operated in multiple reaction monitoring (MRM) mode using the following transitions monitored simultaneously: positive m/z 150.0/91.0 for phentermine, m/z 452.1/344.3 for doxazosin, and negative m/z 338.3/77.9 for topiramate, m/z 355.0/41.9 for pioglitazone.",Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25668796/),,452.1,182761,DB01132,Pioglitazone
,25668796,m/z,"The determination was carried out on an API 4000 triple-quadrupole mass spectrometer operated in multiple reaction monitoring (MRM) mode using the following transitions monitored simultaneously: positive m/z 150.0/91.0 for phentermine, m/z 452.1/344.3 for doxazosin, and negative m/z 338.3/77.9 for topiramate, m/z 355.0/41.9 for pioglitazone.",Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25668796/),,344.3,182762,DB01132,Pioglitazone
,25668796,m/z,"The determination was carried out on an API 4000 triple-quadrupole mass spectrometer operated in multiple reaction monitoring (MRM) mode using the following transitions monitored simultaneously: positive m/z 150.0/91.0 for phentermine, m/z 452.1/344.3 for doxazosin, and negative m/z 338.3/77.9 for topiramate, m/z 355.0/41.9 for pioglitazone.",Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25668796/),,338.3,182763,DB01132,Pioglitazone
,25668796,m/z,"The determination was carried out on an API 4000 triple-quadrupole mass spectrometer operated in multiple reaction monitoring (MRM) mode using the following transitions monitored simultaneously: positive m/z 150.0/91.0 for phentermine, m/z 452.1/344.3 for doxazosin, and negative m/z 338.3/77.9 for topiramate, m/z 355.0/41.9 for pioglitazone.",Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25668796/),,77.9,182764,DB01132,Pioglitazone
,25668796,m/z,"The determination was carried out on an API 4000 triple-quadrupole mass spectrometer operated in multiple reaction monitoring (MRM) mode using the following transitions monitored simultaneously: positive m/z 150.0/91.0 for phentermine, m/z 452.1/344.3 for doxazosin, and negative m/z 338.3/77.9 for topiramate, m/z 355.0/41.9 for pioglitazone.",Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25668796/),,355.0,182765,DB01132,Pioglitazone
,25668796,m/z,"The determination was carried out on an API 4000 triple-quadrupole mass spectrometer operated in multiple reaction monitoring (MRM) mode using the following transitions monitored simultaneously: positive m/z 150.0/91.0 for phentermine, m/z 452.1/344.3 for doxazosin, and negative m/z 338.3/77.9 for topiramate, m/z 355.0/41.9 for pioglitazone.",Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25668796/),,41.9,182766,DB01132,Pioglitazone
,25549928,Inhibitory concentration (IC50),Inhibitory concentration (IC50) was 12.1 μM.,"Effects of pioglitazone on the pharmacokinetics of nifedipine and its main metabolite, dehydronifedipine, in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25549928/),μM,12.1,183915,DB01132,Pioglitazone
,25549928,absolute bioavailability (AB),"Consequently, the absolute bioavailability (AB) of nifedipine in the presence of pioglitazone (1.0 mg/kg) was significantly higher (25.3 %) than that of the control.","Effects of pioglitazone on the pharmacokinetics of nifedipine and its main metabolite, dehydronifedipine, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25549928/),%,25.3,183916,DB01132,Pioglitazone
,28093968,retention times,"The retention times of etodolac and the IS were 0.77 min and 0.57 min each, indicating the high-throughput potential of the proposed method.",Quantification of Etodolac in Human Plasma for Pharmacokinetics and Bioequivalence Studies in 27 Korean Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28093968/),min,0.77,192870,DB01132,Pioglitazone
,28093968,retention times,"The retention times of etodolac and the IS were 0.77 min and 0.57 min each, indicating the high-throughput potential of the proposed method.",Quantification of Etodolac in Human Plasma for Pharmacokinetics and Bioequivalence Studies in 27 Korean Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28093968/),min,0.57,192871,DB01132,Pioglitazone
,28093968,Area under plasma concentration-time curve (AUCt),"The pharmacokinetic parameters were calculated from the plasma samples and data form the reference and test drugs were represented as follows; Area under plasma concentration-time curve (AUCt) (78.03 vs. 84.00 μgxh/mL), AUC∞ (86.67 vs. 93.92 μgxh/mL), maximal plasma concentration (Cmax) (19.49 vs. 18.94 μg/mL), time for maximal concentrations (Tmax) (2.13 vs. 2.26 h), Plasma elimination half-life (T1/2) (8.12 vs. 8.47 h), elimination rate constant (λz) (0.0853 vs. 0.0818 h-1).",Quantification of Etodolac in Human Plasma for Pharmacokinetics and Bioequivalence Studies in 27 Korean Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28093968/),[h·μg] / [ml],78.03,192872,DB01132,Pioglitazone
,28093968,Area under plasma concentration-time curve (AUCt),"The pharmacokinetic parameters were calculated from the plasma samples and data form the reference and test drugs were represented as follows; Area under plasma concentration-time curve (AUCt) (78.03 vs. 84.00 μgxh/mL), AUC∞ (86.67 vs. 93.92 μgxh/mL), maximal plasma concentration (Cmax) (19.49 vs. 18.94 μg/mL), time for maximal concentrations (Tmax) (2.13 vs. 2.26 h), Plasma elimination half-life (T1/2) (8.12 vs. 8.47 h), elimination rate constant (λz) (0.0853 vs. 0.0818 h-1).",Quantification of Etodolac in Human Plasma for Pharmacokinetics and Bioequivalence Studies in 27 Korean Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28093968/),[h·μg] / [ml],84.00,192873,DB01132,Pioglitazone
,28093968,AUC∞,"The pharmacokinetic parameters were calculated from the plasma samples and data form the reference and test drugs were represented as follows; Area under plasma concentration-time curve (AUCt) (78.03 vs. 84.00 μgxh/mL), AUC∞ (86.67 vs. 93.92 μgxh/mL), maximal plasma concentration (Cmax) (19.49 vs. 18.94 μg/mL), time for maximal concentrations (Tmax) (2.13 vs. 2.26 h), Plasma elimination half-life (T1/2) (8.12 vs. 8.47 h), elimination rate constant (λz) (0.0853 vs. 0.0818 h-1).",Quantification of Etodolac in Human Plasma for Pharmacokinetics and Bioequivalence Studies in 27 Korean Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28093968/),[h·μg] / [ml],86.67,192874,DB01132,Pioglitazone
,28093968,AUC∞,"The pharmacokinetic parameters were calculated from the plasma samples and data form the reference and test drugs were represented as follows; Area under plasma concentration-time curve (AUCt) (78.03 vs. 84.00 μgxh/mL), AUC∞ (86.67 vs. 93.92 μgxh/mL), maximal plasma concentration (Cmax) (19.49 vs. 18.94 μg/mL), time for maximal concentrations (Tmax) (2.13 vs. 2.26 h), Plasma elimination half-life (T1/2) (8.12 vs. 8.47 h), elimination rate constant (λz) (0.0853 vs. 0.0818 h-1).",Quantification of Etodolac in Human Plasma for Pharmacokinetics and Bioequivalence Studies in 27 Korean Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28093968/),[h·μg] / [ml],93.92,192875,DB01132,Pioglitazone
,28093968,maximal plasma concentration (Cmax),"The pharmacokinetic parameters were calculated from the plasma samples and data form the reference and test drugs were represented as follows; Area under plasma concentration-time curve (AUCt) (78.03 vs. 84.00 μgxh/mL), AUC∞ (86.67 vs. 93.92 μgxh/mL), maximal plasma concentration (Cmax) (19.49 vs. 18.94 μg/mL), time for maximal concentrations (Tmax) (2.13 vs. 2.26 h), Plasma elimination half-life (T1/2) (8.12 vs. 8.47 h), elimination rate constant (λz) (0.0853 vs. 0.0818 h-1).",Quantification of Etodolac in Human Plasma for Pharmacokinetics and Bioequivalence Studies in 27 Korean Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28093968/),[μg] / [ml],19.49,192876,DB01132,Pioglitazone
,28093968,maximal plasma concentration (Cmax),"The pharmacokinetic parameters were calculated from the plasma samples and data form the reference and test drugs were represented as follows; Area under plasma concentration-time curve (AUCt) (78.03 vs. 84.00 μgxh/mL), AUC∞ (86.67 vs. 93.92 μgxh/mL), maximal plasma concentration (Cmax) (19.49 vs. 18.94 μg/mL), time for maximal concentrations (Tmax) (2.13 vs. 2.26 h), Plasma elimination half-life (T1/2) (8.12 vs. 8.47 h), elimination rate constant (λz) (0.0853 vs. 0.0818 h-1).",Quantification of Etodolac in Human Plasma for Pharmacokinetics and Bioequivalence Studies in 27 Korean Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28093968/),[μg] / [ml],18.94,192877,DB01132,Pioglitazone
,28093968,time for maximal concentrations (Tmax),"The pharmacokinetic parameters were calculated from the plasma samples and data form the reference and test drugs were represented as follows; Area under plasma concentration-time curve (AUCt) (78.03 vs. 84.00 μgxh/mL), AUC∞ (86.67 vs. 93.92 μgxh/mL), maximal plasma concentration (Cmax) (19.49 vs. 18.94 μg/mL), time for maximal concentrations (Tmax) (2.13 vs. 2.26 h), Plasma elimination half-life (T1/2) (8.12 vs. 8.47 h), elimination rate constant (λz) (0.0853 vs. 0.0818 h-1).",Quantification of Etodolac in Human Plasma for Pharmacokinetics and Bioequivalence Studies in 27 Korean Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28093968/),h,2.13,192878,DB01132,Pioglitazone
,28093968,time for maximal concentrations (Tmax),"The pharmacokinetic parameters were calculated from the plasma samples and data form the reference and test drugs were represented as follows; Area under plasma concentration-time curve (AUCt) (78.03 vs. 84.00 μgxh/mL), AUC∞ (86.67 vs. 93.92 μgxh/mL), maximal plasma concentration (Cmax) (19.49 vs. 18.94 μg/mL), time for maximal concentrations (Tmax) (2.13 vs. 2.26 h), Plasma elimination half-life (T1/2) (8.12 vs. 8.47 h), elimination rate constant (λz) (0.0853 vs. 0.0818 h-1).",Quantification of Etodolac in Human Plasma for Pharmacokinetics and Bioequivalence Studies in 27 Korean Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28093968/),h,2.26,192879,DB01132,Pioglitazone
,28093968,Plasma elimination half-life (T1/2),"The pharmacokinetic parameters were calculated from the plasma samples and data form the reference and test drugs were represented as follows; Area under plasma concentration-time curve (AUCt) (78.03 vs. 84.00 μgxh/mL), AUC∞ (86.67 vs. 93.92 μgxh/mL), maximal plasma concentration (Cmax) (19.49 vs. 18.94 μg/mL), time for maximal concentrations (Tmax) (2.13 vs. 2.26 h), Plasma elimination half-life (T1/2) (8.12 vs. 8.47 h), elimination rate constant (λz) (0.0853 vs. 0.0818 h-1).",Quantification of Etodolac in Human Plasma for Pharmacokinetics and Bioequivalence Studies in 27 Korean Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28093968/),h,8.12,192880,DB01132,Pioglitazone
,28093968,Plasma elimination half-life (T1/2),"The pharmacokinetic parameters were calculated from the plasma samples and data form the reference and test drugs were represented as follows; Area under plasma concentration-time curve (AUCt) (78.03 vs. 84.00 μgxh/mL), AUC∞ (86.67 vs. 93.92 μgxh/mL), maximal plasma concentration (Cmax) (19.49 vs. 18.94 μg/mL), time for maximal concentrations (Tmax) (2.13 vs. 2.26 h), Plasma elimination half-life (T1/2) (8.12 vs. 8.47 h), elimination rate constant (λz) (0.0853 vs. 0.0818 h-1).",Quantification of Etodolac in Human Plasma for Pharmacokinetics and Bioequivalence Studies in 27 Korean Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28093968/),h,8.47,192881,DB01132,Pioglitazone
,28093968,elimination rate constant (λz),"The pharmacokinetic parameters were calculated from the plasma samples and data form the reference and test drugs were represented as follows; Area under plasma concentration-time curve (AUCt) (78.03 vs. 84.00 μgxh/mL), AUC∞ (86.67 vs. 93.92 μgxh/mL), maximal plasma concentration (Cmax) (19.49 vs. 18.94 μg/mL), time for maximal concentrations (Tmax) (2.13 vs. 2.26 h), Plasma elimination half-life (T1/2) (8.12 vs. 8.47 h), elimination rate constant (λz) (0.0853 vs. 0.0818 h-1).",Quantification of Etodolac in Human Plasma for Pharmacokinetics and Bioequivalence Studies in 27 Korean Subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28093968/),1/[h],0.0853,192882,DB01132,Pioglitazone
,28093968,elimination rate constant (λz),"The pharmacokinetic parameters were calculated from the plasma samples and data form the reference and test drugs were represented as follows; Area under plasma concentration-time curve (AUCt) (78.03 vs. 84.00 μgxh/mL), AUC∞ (86.67 vs. 93.92 μgxh/mL), maximal plasma concentration (Cmax) (19.49 vs. 18.94 μg/mL), time for maximal concentrations (Tmax) (2.13 vs. 2.26 h), Plasma elimination half-life (T1/2) (8.12 vs. 8.47 h), elimination rate constant (λz) (0.0853 vs. 0.0818 h-1).",Quantification of Etodolac in Human Plasma for Pharmacokinetics and Bioequivalence Studies in 27 Korean Subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28093968/),1/[h],0.0818,192883,DB01132,Pioglitazone
,26940171,absolute bioavailability,It is well absorbed with a mean absolute bioavailability of 83% and reaching maximum concentrations in around 1.5h.,Pioglitazone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26940171/),%,83,193093,DB01132,Pioglitazone
,31177048,flow rate,"Prior Chromatographic separation on an Agilent Eclipse Plus C18 (4.6 × 100 mm, 3.5 μm) using gradient mobile phase system consisting of ammonium formate pH 4.5 and acetonitrile at a flow rate of 0.5 mL min-1, within a run time of 14 min, the antidiabetic drugs were extracted from rat plasma using acetonitrile-induced protein precipitation technique.",Liquid chromatography tandem mass spectrometry for the simultaneous determination of metformin and pioglitazone in rat plasma: Application to pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31177048/),[ml] / [min],0.5,194137,DB01132,Pioglitazone
,31177048,run time,"Prior Chromatographic separation on an Agilent Eclipse Plus C18 (4.6 × 100 mm, 3.5 μm) using gradient mobile phase system consisting of ammonium formate pH 4.5 and acetonitrile at a flow rate of 0.5 mL min-1, within a run time of 14 min, the antidiabetic drugs were extracted from rat plasma using acetonitrile-induced protein precipitation technique.",Liquid chromatography tandem mass spectrometry for the simultaneous determination of metformin and pioglitazone in rat plasma: Application to pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31177048/),min,14,194138,DB01132,Pioglitazone
,31177048,m/z,"Multiple reaction monitoring in positive ion mode was used for quantitation of precursor to production at m/z 130.1 → 71.0 & 60 for MET, 357.2 → 134.2 for PGT, and 462.16 → 191.1 for CAN.",Liquid chromatography tandem mass spectrometry for the simultaneous determination of metformin and pioglitazone in rat plasma: Application to pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31177048/),,130.1,194139,DB01132,Pioglitazone
,31177048,m/z,"Multiple reaction monitoring in positive ion mode was used for quantitation of precursor to production at m/z 130.1 → 71.0 & 60 for MET, 357.2 → 134.2 for PGT, and 462.16 → 191.1 for CAN.",Liquid chromatography tandem mass spectrometry for the simultaneous determination of metformin and pioglitazone in rat plasma: Application to pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31177048/),,71,194140,DB01132,Pioglitazone
,31177048,m/z,"Multiple reaction monitoring in positive ion mode was used for quantitation of precursor to production at m/z 130.1 → 71.0 & 60 for MET, 357.2 → 134.2 for PGT, and 462.16 → 191.1 for CAN.",Liquid chromatography tandem mass spectrometry for the simultaneous determination of metformin and pioglitazone in rat plasma: Application to pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31177048/),,357.2,194141,DB01132,Pioglitazone
,31177048,m/z,"Multiple reaction monitoring in positive ion mode was used for quantitation of precursor to production at m/z 130.1 → 71.0 & 60 for MET, 357.2 → 134.2 for PGT, and 462.16 → 191.1 for CAN.",Liquid chromatography tandem mass spectrometry for the simultaneous determination of metformin and pioglitazone in rat plasma: Application to pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31177048/),,134.2,194142,DB01132,Pioglitazone
,31177048,m/z,"Multiple reaction monitoring in positive ion mode was used for quantitation of precursor to production at m/z 130.1 → 71.0 & 60 for MET, 357.2 → 134.2 for PGT, and 462.16 → 191.1 for CAN.",Liquid chromatography tandem mass spectrometry for the simultaneous determination of metformin and pioglitazone in rat plasma: Application to pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31177048/),,462.16,194143,DB01132,Pioglitazone
,31177048,m/z,"Multiple reaction monitoring in positive ion mode was used for quantitation of precursor to production at m/z 130.1 → 71.0 & 60 for MET, 357.2 → 134.2 for PGT, and 462.16 → 191.1 for CAN.",Liquid chromatography tandem mass spectrometry for the simultaneous determination of metformin and pioglitazone in rat plasma: Application to pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31177048/),,191.1,194144,DB01132,Pioglitazone
,34211797,flow rate,0.02% formic acid aqueous solution (A) and methanol-acetonitrile (B) were used as mobile phases with gradient elution at a flow rate of 0.3 mL/min.,Simultaneous Quantification of Pioglitazone and Omarigliptin in Rat Plasma by UHPLC-MS/MS and Its Application to Pharmacokinetic Study after Coadministration of the Two Drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34211797/),[ml] / [min],0.3,194391,DB01132,Pioglitazone
,31340601,transdermal flux,The ex vivo permeation results substantiate the release data as a greater transdermal flux (15.67 ± 2.35 µg/cm2/h) was demonstrated in patch fabricated with Duro-Tak 87-2516.,Effective Therapeutic Delivery and Bioavailability Enhancement of Pioglitazone Using Drug in Adhesive Transdermal Patch. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31340601/),[μg] / [cm2·h],15.67,203102,DB01132,Pioglitazone
,31340601,maximum solubility,The maximum solubility of pioglitazone in Duro-Tak 87-2516 was found to be 6% w/w.,Effective Therapeutic Delivery and Bioavailability Enhancement of Pioglitazone Using Drug in Adhesive Transdermal Patch. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31340601/),[%·w] / [w],6,203103,DB01132,Pioglitazone
,31340601,AUC0-α,"In vivo pharmacokinetic data demonstrate that the AUC0-α in transdermal application (13,506.51 ± 1649.92 ng·h/mL) was ~2 times higher (p < 0.0001) as compared to oral dosage form.",Effective Therapeutic Delivery and Bioavailability Enhancement of Pioglitazone Using Drug in Adhesive Transdermal Patch. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31340601/),[h·ng] / [ml],"13,506.51",203104,DB01132,Pioglitazone
,26079265,limits of detection,"The limits of detection (S/N=3) and quantification (S/N=10) were 0.16 and 0.5ngmL(-1), respectively.",An efficient hydrophilic interaction liquid chromatographic method for the simultaneous determination of metformin and pioglitazone using high-purity silica column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26079265/),,3,203527,DB01132,Pioglitazone
,26079265,S/N,"The limits of detection (S/N=3) and quantification (S/N=10) were 0.16 and 0.5ngmL(-1), respectively.",An efficient hydrophilic interaction liquid chromatographic method for the simultaneous determination of metformin and pioglitazone using high-purity silica column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26079265/),,3,203528,DB01132,Pioglitazone
,26079265,S/N,"The limits of detection (S/N=3) and quantification (S/N=10) were 0.16 and 0.5ngmL(-1), respectively.",An efficient hydrophilic interaction liquid chromatographic method for the simultaneous determination of metformin and pioglitazone using high-purity silica column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26079265/),1/[ngml],10,203529,DB01132,Pioglitazone
,26079265,S/N,"The limits of detection (S/N=3) and quantification (S/N=10) were 0.16 and 0.5ngmL(-1), respectively.",An efficient hydrophilic interaction liquid chromatographic method for the simultaneous determination of metformin and pioglitazone using high-purity silica column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26079265/),1/[ngml],0.16,203530,DB01132,Pioglitazone
,26079265,S/N,"The limits of detection (S/N=3) and quantification (S/N=10) were 0.16 and 0.5ngmL(-1), respectively.",An efficient hydrophilic interaction liquid chromatographic method for the simultaneous determination of metformin and pioglitazone using high-purity silica column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26079265/),1/[ngml],0.5,203531,DB01132,Pioglitazone
,26079265,retention times,"The retention times were 3.4 and 5.0min for PIO and MET, respectively.",An efficient hydrophilic interaction liquid chromatographic method for the simultaneous determination of metformin and pioglitazone using high-purity silica column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26079265/),min,3.4,203532,DB01132,Pioglitazone
,26079265,retention times,"The retention times were 3.4 and 5.0min for PIO and MET, respectively.",An efficient hydrophilic interaction liquid chromatographic method for the simultaneous determination of metformin and pioglitazone using high-purity silica column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26079265/),min,5.0,203533,DB01132,Pioglitazone
,29403738,flow rate,The reconstituted samples were chromatographed on a C18 column by using a 80:20 (v/v) mixture of acetonitrile and 0.1% formic acid as the mobile phase at a flow rate of 0.8 mL/min.,Simultaneous determination of pioglitazone and candesartan in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403738/),[ml] / [min],0.8,208533,DB01132,Pioglitazone
,29403738,run time,A run time of 2.7 min for each sample made it possible to analyze more than 300 plasma samples per day.,Simultaneous determination of pioglitazone and candesartan in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403738/),min,2.7,208534,DB01132,Pioglitazone
,23618742,flow rate,"The mobile phase was acetonitrile: 5mM ammonium formate containing 0.3% formic acid (pH 4.8) (25:75, v/v), with a flow rate of 0.35mL/min.",Simultaneous determination of iloperidone and its two active metabolites in human plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23618742/),[ml] / [min],0.35,231535,DB01132,Pioglitazone
more,23618742,recoveries,"The mean recoveries were more than 78.88%, and the intra- and inter-day precisions were less than 10.24% and accuracy was -5.78 to 5.40%, which indicated that the quantitative method was reliable and accurate.",Simultaneous determination of iloperidone and its two active metabolites in human plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23618742/),%,78.88,231536,DB01132,Pioglitazone
,14522601,AUCs,"The AUCs of pioglitazone (149.6+/-22.6 vs. 103.3+/-14.0 microg.h/ml; P<0.01), M-III (31.4+/-8.1 vs. 20.2+/-4.7 microg.h/ml; P<0.05) and M-IV (41.9+/-15.5 vs. 14.1+/-1.6 microg.h/ml; P<0.01) were larger in female rats than in male rats, but the levels of M-II were similar.",Sex differences in the pharmacokinetics of pioglitazone in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522601/),[h·μg] / [ml],149.6,231737,DB01132,Pioglitazone
,14522601,AUCs,"The AUCs of pioglitazone (149.6+/-22.6 vs. 103.3+/-14.0 microg.h/ml; P<0.01), M-III (31.4+/-8.1 vs. 20.2+/-4.7 microg.h/ml; P<0.05) and M-IV (41.9+/-15.5 vs. 14.1+/-1.6 microg.h/ml; P<0.01) were larger in female rats than in male rats, but the levels of M-II were similar.",Sex differences in the pharmacokinetics of pioglitazone in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522601/),[h·μg] / [ml],103.3,231738,DB01132,Pioglitazone
,14522601,AUCs,"The AUCs of pioglitazone (149.6+/-22.6 vs. 103.3+/-14.0 microg.h/ml; P<0.01), M-III (31.4+/-8.1 vs. 20.2+/-4.7 microg.h/ml; P<0.05) and M-IV (41.9+/-15.5 vs. 14.1+/-1.6 microg.h/ml; P<0.01) were larger in female rats than in male rats, but the levels of M-II were similar.",Sex differences in the pharmacokinetics of pioglitazone in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522601/),[h·μg] / [ml],31.4,231739,DB01132,Pioglitazone
,14522601,AUCs,"The AUCs of pioglitazone (149.6+/-22.6 vs. 103.3+/-14.0 microg.h/ml; P<0.01), M-III (31.4+/-8.1 vs. 20.2+/-4.7 microg.h/ml; P<0.05) and M-IV (41.9+/-15.5 vs. 14.1+/-1.6 microg.h/ml; P<0.01) were larger in female rats than in male rats, but the levels of M-II were similar.",Sex differences in the pharmacokinetics of pioglitazone in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522601/),[h·μg] / [ml],20.2,231740,DB01132,Pioglitazone
,14522601,AUCs,"The AUCs of pioglitazone (149.6+/-22.6 vs. 103.3+/-14.0 microg.h/ml; P<0.01), M-III (31.4+/-8.1 vs. 20.2+/-4.7 microg.h/ml; P<0.05) and M-IV (41.9+/-15.5 vs. 14.1+/-1.6 microg.h/ml; P<0.01) were larger in female rats than in male rats, but the levels of M-II were similar.",Sex differences in the pharmacokinetics of pioglitazone in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522601/),[h·μg] / [ml],41.9,231741,DB01132,Pioglitazone
,14522601,AUCs,"The AUCs of pioglitazone (149.6+/-22.6 vs. 103.3+/-14.0 microg.h/ml; P<0.01), M-III (31.4+/-8.1 vs. 20.2+/-4.7 microg.h/ml; P<0.05) and M-IV (41.9+/-15.5 vs. 14.1+/-1.6 microg.h/ml; P<0.01) were larger in female rats than in male rats, but the levels of M-II were similar.",Sex differences in the pharmacokinetics of pioglitazone in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522601/),[h·μg] / [ml],14.1,231742,DB01132,Pioglitazone
,16390353,elimination half-life (t(1/2)),Rifampicin decreased the mean total area under the plasma concentration-time curve (AUC(0-infinity)) of pioglitazone by 54% (range 20-66%; P = 0.0007; 95% confidence interval -78 to -30%) and shortened its dominant elimination half-life (t(1/2)) from 4.9 to 2.3 h (P = 0.0002).,Effect of rifampicin on the pharmacokinetics of pioglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390353/),h,4.9,235492,DB01132,Pioglitazone
,16390353,elimination half-life (t(1/2)),Rifampicin decreased the mean total area under the plasma concentration-time curve (AUC(0-infinity)) of pioglitazone by 54% (range 20-66%; P = 0.0007; 95% confidence interval -78 to -30%) and shortened its dominant elimination half-life (t(1/2)) from 4.9 to 2.3 h (P = 0.0002).,Effect of rifampicin on the pharmacokinetics of pioglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390353/),h,2.3,235493,DB01132,Pioglitazone
,27260150,half-life,"Clopidogrel increased the area under the plasma concentration-time curve (AUC0-∞) of pioglitazone 2.1-fold [P < 0.001, 90% confidence interval (CI) 1.8-2.6] and prolonged its half-life from 6.7 to 11 hours (P = 0.002).",Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27260150/),h,6.7,249674,DB01132,Pioglitazone
,27260150,half-life,"Clopidogrel increased the area under the plasma concentration-time curve (AUC0-∞) of pioglitazone 2.1-fold [P < 0.001, 90% confidence interval (CI) 1.8-2.6] and prolonged its half-life from 6.7 to 11 hours (P = 0.002).",Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27260150/),h,11,249675,DB01132,Pioglitazone
,31704620,flow rate,"Chromatographic separation was achieved on C8 (50 × 4.6 mm, 5 μm) Kinetex® analytical column using methanol and 0.1% formic acid in a gradient elution mode at a flow rate of 0.7 mL/min with injection volume of 8 μL.","Determination of pioglitazone, its metabolite and alogliptin in human plasma by a novel LC-MS/MS method; application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31704620/),[ml] / [min],0.7,250324,DB01132,Pioglitazone
,31704620,injection volume,"Chromatographic separation was achieved on C8 (50 × 4.6 mm, 5 μm) Kinetex® analytical column using methanol and 0.1% formic acid in a gradient elution mode at a flow rate of 0.7 mL/min with injection volume of 8 μL.","Determination of pioglitazone, its metabolite and alogliptin in human plasma by a novel LC-MS/MS method; application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31704620/),μl,8,250325,DB01132,Pioglitazone
,28528664,flow rate,"Chromatographic separation was achieved on a BEH C18 column (50mm×2.1mm, 1.7μm) with 0.1% aqueous formic acid: acetonitrile (40:60, v/v) at a flow rate of 0.3mLmin-1.",Enhanced LC-MS/MS analysis of alogliptin and pioglitazone in human plasma: Applied to a preliminary pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28528664/),1/[mlmin],0.3,251161,DB01132,Pioglitazone
,28528664,m/z,"Monitoring the transition pairs of m/z 340.18 to 116.08 for alogliptin and m/z 356.99 to 133.92 for pioglitazone, using triple quadrupole mass spectrometer with multiple reaction monitoring, was achieved in the positive mode.",Enhanced LC-MS/MS analysis of alogliptin and pioglitazone in human plasma: Applied to a preliminary pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28528664/),,340.18 to 116.08,251162,DB01132,Pioglitazone
,28528664,m/z,"Monitoring the transition pairs of m/z 340.18 to 116.08 for alogliptin and m/z 356.99 to 133.92 for pioglitazone, using triple quadrupole mass spectrometer with multiple reaction monitoring, was achieved in the positive mode.",Enhanced LC-MS/MS analysis of alogliptin and pioglitazone in human plasma: Applied to a preliminary pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28528664/),,356.99,251163,DB01132,Pioglitazone
,17913794,inhibition constant,"Trimethoprim inhibited M-IV formation in vitro (inhibition constant 38.2 muM), predicting the in vivo interaction.",Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17913794/),muM,38.2,271534,DB01132,Pioglitazone
